

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

Intrapartum intravenous fluids for caesarean delivery and newborn weight loss

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2017-000070
Article Type:	Original article
Date Submitted by the Author:	08-May-2017
Complete List of Authors:	Eltonsy, Sherif; Centre de formation médicale du Nouveau-Brunswick Blinn, Alain; Université de Sherbrooke, Department of family medicine Sonier, Brigitte; Research Centre, Vitalité Health Network Deroche, Steven; Université de Sherbrooke Faculté de médecine et des sciences de la santé Mulaja, Aubin; Université de Sherbrooke Faculté de médecine et des sciences de la santé Hynes, William; Université de Sherbrooke Faculté de médecine et des sciences de la santé Barrieau, André; Université de Sherbrooke Faculté de médecine et des sciences de la santé Belanger, Mathieu; Centre de formation médicale du Nouveau-Brunswick; Université de Sherbrooke Faculté de médecine et des sciences de la santé
Keywords:	Epidemiology, Neonatology, Therapeutics

SCHOLARONE™
Manuscripts

Intrapartum intravenous fluids for caesarean delivery and newborn weight loss

Sherif Eltonsy PhD^{1,2}, Alain Blinn MD^{3,4}, Brigitte Sonier PhD⁵, Steven DeRoche MD^{3,4}, Aubin Mulaja MD^{3,4}, William Hynes MD^{3,4}, André Barrieau MD^{3,4}, Mathieu Bélanger PhD^{1,3,4,5*}

¹ Centre de formation médicale du Nouveau-Brunswick (Moncton, Canada)

² The Maritime SPOR SUPPORT Unit (MSSU) (Moncton, Canada)

³ Department of family medicine, Université de Sherbrooke (Sherbrooke, Canada)

⁴ Dieppe Family Medicine Unit (Dieppe, Canada)

⁵ Research Centre, Vitalité Health Network (Moncton, Canada)

***Corresponding author:** Mathieu Bélanger, PhD

Centre de formation médicale du Nouveau-Brunswick

Pavillon J.-Raymond-Frenette

15, rue des Aboiteaux

Moncton, NB Canada E1A 3E9

+1 506 863 2221 (phone)

+1 506 863 2284 (fax)

mathieu.f.belanger@usherbrooke.ca

Word count: 2500

Keywords: Birth weight, Weight loss, Colloids, Crystalloids, Caesarean section.

ABSTRACT

Objective: To examine weight loss (WL) and excess weight loss (EWL) among newborns of caesarean delivery, comparing colloids plus crystalloids versus crystalloids only. Also, to examine different doses of intrapartum intravenous fluids (IVF) on WL and EWL.

Design: Comparative safety retrospective cohort study.

Setting: University teaching hospital, Moncton, Canada.

Patients: Mothers exposed to IVF with caesarean delivery between 2008 and 2016.

Interventions: Exposure to colloids plus crystalloids was compared to crystalloids only, and dose-response analyses were performed for colloids, crystalloids and total IVF doses. Linear and logistic regression models were used, adjusting for potential confounders.

Main outcome measures: Infants' WL was measured at days 1, 2 and 3 postpartum, and EWL defined as loss of > 7% of birth weight.

Results: From 801 mother-infant pairs, 176 were exposed to colloids plus crystalloids and 625 were exposed to crystalloids only (overall mean birth weight = 3416 g, EWL = 2%, 41.4% and 55.5% on days 1, 2 and 3 respectively). No significant difference in newborns' WL was observed on any of the days assessed. Adjusted odds ratio (95% CI) of EWL was 1.0 (0.3–3.3) at 24 hours, 1.0 (0.7–1.5) at 48 hours and 1.4 (0.9–2.2) at 72 hours. No dose-response relationship was detected with type-specific and total IVF exposures.

Conclusions: The risk of EWL was similar with colloids plus crystalloids and crystalloids only, suggesting that both therapeutic options can be considered during

1
2
3 caesarean delivery. The absence of dose-response relationships adds confirmatory
4
5 evidence to the IVF safety profiles.
6
7

8 **Keywords:** Birth weight, Weight loss, Colloids, Crystalloids, Caesarean section.
9
10

11 12 13 14 15 **INTRODUCTION**

16
17 Hypotension is the most significant adverse effect in women undergoing spinal anaesthesia
18
19 for caesarean delivery, affecting on average 70% of pregnant women.[1,2] The
20
21 administration of intravenous (IV) fluids (i.e. crystalloids and colloids) prior to and/or
22
23 during anaesthesia represents one of the most common strategies to prevent maternal
24
25 hypotension.[1] Among the IV fluids, crystalloid solutions are the most frequently used,
26
27 with normal saline (NS) and Ringer's lactate (RL) as the most common choices.[3]
28
29 Systematic reviews and meta-analyses indicate that pre- or co-loading with colloids –
30
31 specifically hydroxyethyl starches (HES) – is superior to crystalloids alone, with volumes
32
33 larger than 500 ml offering no significant additional benefits.[1–5] Current practice
34
35 advocate combining colloids and crystalloids solutions rather than colloids alone.[2]
36
37
38
39
40
41
42

43 While colloids are becoming an increasingly used choice as IV fluid in pregnant women
44
45 undergoing caesarean section, no study has examined the impact of colloids – or colloids
46
47 plus crystalloids combination – on excess weight loss (EWL) among newborns. Although
48
49 normal physiological weight loss occurs after delivery,[6,7] EWL (i.e. loss of more than
50
51 7-10% of birth weight) is considered a complication which increases the risk of
52
53
54
55 hyperbilirubinemia, hypernatremic dehydration, hospitalizations and long-term
56
57
58
59
60

1
2
3 morbidity.[8–10] Recent literature reports growing evidence of positive association
4
5 between IV fluids – specifically crystalloids – and EWL (between 7% to 10%),[11–14]
6
7 and it remains unclear whether different IV fluid combinations present similar safety
8
9 profiles. The primary objective of the current study was to examine amount of weight
10
11 loss and EWL among newborns of caesarean delivery, comparing colloids plus
12
13 crystalloids intrapartum IV fluids versus crystalloids only. The secondary objective was
14
15 to examine the association between different doses of intrapartum IV fluids and newborn
16
17 weight loss, as well as EWL.
18
19
20
21
22
23

24 **METHODS**

25 **Study Design**

26
27 A population-based retrospective cohort design was used. The cohort was selected from
28
29 mothers hospitalized at the Dr. George-L.-Dumont University Hospital Centre (New
30
31 Brunswick, Canada) between April 2008 and June 2016. Trained medical staff extracted
32
33 the information from the hospital medical records of mothers undergoing caesarean
34
35 deliveries and their linked newborns' files. Data collection was performed on two periods
36
37 for logistical and sample size reasons; (1) records from all (n = 320) caesarean deliveries
38
39 between April 2008 and January 2010 and (2) a random sample of 500 caesarean
40
41 deliveries between February 2010 and June 2016 were retained. Performing separate
42
43 primary analysis for the two periods did not show major differences in results.
44
45
46
47
48
49

50 **Cohort Selection**

51
52 The cohort inclusion criteria were: (1) a pregnancy with a recorded caesarean delivery
53
54 between April 1, 2008 and June 31, 2016; (2) recorded singleton live birth; (3) maternal
55
56
57
58
59
60

age at the beginning of pregnancy of 15-45 years; (4) gestational duration of 20-45 weeks; and (5) exposure to colloids or crystalloids IV fluids before caesarean delivery.

The exclusion criteria were: (1) missing data on IV fluids administration and other potential variables and (2) infants with feeding difficulties leading to unsuccessful oral feeding (neither breastfeeding nor formula) during the hospitalization period (i.e nil per os [NPO]).

Weight Loss and EWL

From the infants' medical records, we extracted information on birth weight and infants' weight at 24, 48 and 72 hours. EWL was defined as loss of > 7% of birth weight, calculated at 24, 48 and 72 hours postpartum.[6,7,15]

IV Fluids Exposure

Colloids (Voluven®, Pentaspan® and others/non specified) plus crystalloids (RL, NS and others/non specified) use was defined as the maternal intrapartum exposure to both colloids and crystalloids IV fluids for caesarean delivery. Crystalloids use (RL, NS and others/non specified) was defined as the maternal intrapartum exposure to crystalloids only. The doses of colloids were categorized as: 0, > 0-500, > 500 ml and doses of crystalloids were categorized as: 0, > 0-1000, > 1000-2000, > 2000 ml. We calculated the total doses of IV fluids; categorized into: 0-1000, > 1000-2000, > 2000-3000, > 3000ml.

Confounding Variables

Two classes of potential risk factors were included in the analysis. First, gestational and maternal variables, including: maternal age in years at delivery, number of pregnancies, number of viable births, number of lost pregnancies, gestational diabetes (yes/no), hypertension during pregnancy (yes/no), pre-eclampsia (yes/no), cigarette smoking

1
2
3 during pregnancy (yes/no), alcohol drinking during pregnancy (yes/no), drug use during
4 pregnancy (yes/no), epidural before caesarean section (yes/no), and elective caesarean
5 section (yes/no). Second, infant related variables, including: gestational age in weeks,
6 Apgar score, fever during hospitalization (yes/no), breastfeeding during hospitalization
7 (yes/no), phototherapy on days 1 (yes/no), 2 (yes/no) and 3 (yes/no), number of urine on
8 each of day 1, 2 and 3, and number of stools on each of day 1, 2 and 3.
9

10 11 12 13 14 15 16 17 18 **Statistical Analysis**

19
20 The descriptive statistics for the characteristics of the mothers-infants pairs were
21 calculated and compared between groups. We compared the amount of weight lost by
22 infants in both groups at 24, 48 and 72 hours postpartum using crude and adjusted linear
23 regressions, with crystalloids only users as reference group. Three regression models
24 were constructed: *Model 1* (crude), *Model 2* (adjusted for maternal age, gestational
25 diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost
26 pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use,
27 epidural before caesarean section, and elective caesarean section) and *Model 3* (adjusted
28 for the variables in Model 2, in addition to Apgar score, breastfeeding, number of stools,
29 number of urine, presence of fever and phototherapy). The purpose of this methodology
30 is that the additional variables in Model 3 were measured during the postpartum period
31 and not at baseline, and through them, the effect of IV fluids on weight loss could be
32 mediated.
33

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Additional regression models for colloids and crystalloids doses were used to examine trends and dose-response relationships with newborn weight loss, similarly with the total IV fluid doses. Logistic regression models were used to estimate crude and adjusted odds

ratios (ORs) and 95% confidence intervals (CIs) for EWL, with adjustment for potential confounders as listed above. Firth penalized maximum likelihood estimation method was used whenever quasi-complete separation in data was detected in logistic regression models.[16]

Sensitivity Analysis

First, the maximum physiological limits of weight loss for newborns are controversial,[17,18] thus, we reanalyzed our data using EWL defined as (1) loss of > 5% and (2) loss of > 10% of birth weight. Second, suboptimal breastfeeding and delayed onset of lactogenesis can lead to EWL.[11,15] Therefore, we tested its potential effect using 2 different techniques; (1) performed all analyses among the subgroup of breastfed newborns only and (2) excluded breastfeeding as potential confounder from Model 3. Using a type I error of 0.05 and 80% power, a sample size of 818 mother-infants pairs was estimated to be sufficient to detect a between-group weight loss difference of 10%. All statistical analyses were conducted using SAS software, version 9.3 (SAS Institute Inc., Cary, NC). This study was approved by the Research Ethics Committee of the Vitalité Health Network.

RESULTS

A total of 801 mother-infant pairs fulfilled our inclusion and exclusion criteria (see Figure 1 for the selection process). From these, 176 mother-infant pairs were exposed to colloids plus crystalloids intrapartum and 625 were exposed to crystalloids only. Among the colloids plus crystalloids group, 58.5% were exposed to Voluven®, 12.5% to Pentaspan®, and 29% to other colloids or non-specified. For crystalloids, 87.3% were

1
2
3 exposed to RL only, 7.1% to RL and NS, and 5.6% to other crystalloids or non-specified.
4
5
6 The most frequently used doses of colloids and crystalloids were > 500 ml and >1000-
7
8 2000 ml, respectively. Overall, the mean birth weight for the newborns was 3416 g.
9
10 During the hospitalization period, EWL of > 7% was detected in 15 infants (2%) at 24
11
12 hours, 318 infants (41.4%) at 48 hours, 351 infants (55.5%) at 72 hours, and EWL of >
13
14 10% was detected in 3 infants (0.4%) at 24 hours, 17 infants (2.2%) at 48 hours and 100
15
16 infants (15.8%) at 72 hours.
17
18
19
20
21

22 In both groups, most women were ≤ 35 years of age, with approximately 1 to 4 gravidity,
23
24 0 to 1 parity and 0 to 1 abortus (Table I). However, women exposed to crystalloids only
25
26 were more likely to have suffered from gestational diabetes, to have been exposed to
27
28 epidural before caesarean section, to report cigarette smoking and alcohol drinking. The
29
30 incidence of preterm deliveries and phototherapy on day 3 were higher among infants in
31
32 the colloids plus crystalloids group, while breastfeeding during hospitalization was more
33
34 successful in the crystalloids only group.
35
36
37
38
39
40

41 **Differences in Weight**

42 We observed no significant difference in newborns' weight loss between women exposed
43
44 to colloids plus crystalloids compared to crystalloids only intrapartum on any of the three
45
46 days assessed (Table II). Moreover, none of the doses of colloids, crystalloids or total IV
47
48 fluids was found to be associated with a significant difference in weight loss, nor with a
49
50 trend of increased or decreased risk over time. We obtained similar estimates for Models
51
52
53
54
55
56
57
58
59
60 2 and 3 (only results from Model 3 are presented, others are available upon request).

Differences in EWL by Group

We observed no significant difference in the risk of EWL (>7%) at 24 hours (adjusted OR: 1.0; 95% CI: 0.3–3.3), 48 hours (adjusted OR: 1.0; 95% CI: 0.7–1.5) or 72 hours (adjusted OR: 1.4; 95% CI: 0.9–2.2) (Table III). Elective caesarean section was associated with a significant increased risk of EWL at 48 hours (adjusted OR: 1.7; 95% CI: 1.1–2.6) and at 72 hours (adjusted OR: 1.8; 95% CI: 1.1–2.9). Number of stools measured on each day was significantly associated with EWL (adjusted OR, 95% CI: 1.6, 1.1–2.3; 0.8, 0.7–0.9; and 0.7, 0.6–0.8 at 24, 48 and 72 hours, respectively). We obtained similar estimates for Models 2 and 3.

Differences in EWL by Dose

At 24 hours postpartum, the number of cases of EWL was too small to examine specific crystalloids doses. However, neither colloids doses nor total IV fluids doses were associated significantly with EWL (Table IV). At 48 and 72 hours postpartum, we observed no significant association between colloids, crystalloids or total IV fluids and EWL, with the exception of a marginal protective effect from EWL at 72 hours postpartum for crystalloids at doses >1000-2000 (adjusted OR: 0.2; 95% CI: <0.1–0.9). No trend or dose-response relationship was observed with the increase in doses of intrapartum IV fluids (Table IV). Results from the 3 sensitivity analyses supported the primary analyses estimates (results are available upon request).

DISCUSSION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This comparative safety study revealed two main findings. First, the newborn weight loss and the risk of EWL did not differ when colloids plus crystalloids or crystalloids only IV fluids were administered intrapartum for caesarean delivery. Second, there was no dose-response relationship between colloids, crystalloids or total IV fluids and an increased risk of EWL. The results were consistent in different models and sensitivity analyses on breastfed newborns and EWL of >5% and >10% showed similar results.

To the best of our knowledge, this study is the first to compare the risk of EWL for different types of intrapartum IV fluids for caesarean delivery. Previous studies have demonstrated comparable neonatal safety profiles of colloids versus crystalloids, specifically for neonatal acidosis (risk ratio [RR] 0.2; 95% CI 0.01-4.1) and Apgar score (meta-analysis of 3 studies with 209 women: RR: 0.2; 95% CI 0.03-2.1).[1] Similarly, no significant difference in Apgar score was found among neonates exposed to colloids plus crystalloids versus crystalloids only (meta-analysis of 2 studies with 107 women: RR: 0.1; 95% CI 0.01-1.2).[1] Still, it is noteworthy that the number of events in those studies was low and medications used in these older trials (e.g dextrans and gelatins) no longer reflect the current practice of using HES as the preferred choice.[2,4,5] Recently, the CAESAR trial compared two treatment regimens similar to the current study and reported no difference in Apgar score or umbilical pH.[2]

Of nine published studies, five reported significant positive associations between doses of intrapartum fluids and weight loss[11–14,19] whereas the other four reported no significant relationships.[20–23] However, studies with significant findings are different

1
2
3 from the current study since they were based on vaginal births and breastfed
4 newborns[11,12,19] or very small sample sizes.[13,14] Our results corroborate the results
5
6 of one case-control[23], two prospective cohort studies[20,22], as well as the only RCT
7
8 on intrapartum IV fluids and EWL to date.[21]
9
10

11
12
13
14
15 Previous studies hypothesized that since fluids move freely from the mother to her fetus,
16
17 newborns may become overhydrated and a consequent correction for the newborns' fluid
18
19 balance is an increase in diuresis and weight loss.[20,24] This hypothesis was partially
20
21 supported by recent reports[11,12], but caution must be exercised as the observed weight
22
23 loss could be attributed to insufficient feeding, especially among breastfed infants.
24
25
26 Previous studies had suggested that the intrapartum administration of crystalloids could
27
28 significantly affect the onset of lactogenesis[12,15,25] through the development of breast
29
30 engorgement, which in turn could negatively affect milk production[25] and increase
31
32 breast edema.[26] However, our results suggest that if this is the case, it will not lead to
33
34 an increased risk of EWL. Future studies are warranted to fully examine the effect of IV
35
36 fluids – and their specific types – on lactogenesis and EWL. A noteworthy finding is the
37
38 significant association between elective caesarean delivery and EWL. It is possible that
39
40 pregnant women opting for an elective caesarean delivery could have suffered from other
41
42 obstetric conditions that leave their newborns more prone to EWL.
43
44
45
46
47
48
49
50

51 The present study has some important strengths. Our objective was to compare newborn
52
53 weight loss and EWL after two widely used prevention and treatment options for
54
55 hypotension during caesarean delivery. Through comparing similar IV fluid regimens,
56
57
58
59
60

1
2
3 and accounting for numerous potentially confounding variables, we minimized the
4 potential bias of confounding by indication, in this case hypotension itself. Indeed,
5 maternal hypotension itself – and the associated reduction in utero-placental blood supply
6 – can lead to fetal acidosis, which cause weak rooting and sucking reflexes. The later
7 factors can severely compromise lactogenesis, leading to significant newborn weight loss
8 that can be erroneously attributed to IV fluids exposure.[1,27–29] In addition, we used a
9 large set of statistical models and sensitivity analyses to confirm the validity of our
10 observed estimates. However, the results should be interpreted with consideration of the
11 following limitations. We were unable to distinguish between pre- and co-loading of IV
12 fluids administered. We did not have data on intrapartum oral fluids nor the exact onset
13 of successful breastfeeding (day 1, 2, or 3). Given that this is a comparative safety study
14 with an active treatment regimen as a reference group, we cannot exclude the possibility
15 that both IV fluid regimens have a deleterious effect on newborn weight loss.
16 Nevertheless, such comparisons (use versus no use) are less clinically relevant because
17 not treating a woman who requires IV fluids for prevention of hypotension is not an
18 option.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 In summary, in the current comparative safety study, the difference in weight loss and the
44 risk of EWL were similar with colloids plus crystalloids and crystalloids intrapartum IV
45 fluids among women undergoing caesarean delivery. The absence of dose-response
46 relationships between both IV fluids types and EWL adds confirmatory evidence to their
47 safety profiles. Combined with previous studies, these results suggest that both
48 therapeutic options can be considered as safe during caesarean sections.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 **Acknowledgements** We thank Mr. Hamza Abdelalim for assistance with the data
9 collection process.
10

11
12 **Competing interests** None declared.
13

14
15 **Provenance and peer review** Not commissioned; externally peer reviewed.
16

17
18 **Data sharing statement** Data are available after discussion with the Oracle Study
19 Investigators in accordance with our data-sharing policy.
20

21
22 **Contribution to Authorship** SE, ABa, BS, SD, AM, WH, ABi and MB have
23 contributed to the concept and design of the study. SE and MB performed the analysis
24 and drafted the first draft. SE, ABa, BS, SD, AM, WH, ABi and MB participated in the
25 interpretation of the data. SE, ABa, BS, SD, AM, WH, ABi and MB contributed in
26 drafting and revising of the full manuscript, and have approved the manuscript as
27 submitted. SE, ABa, BS, SD, AM, WH, ABi and MB have met the criteria of authorship,
28 and take public responsibility for the study contents.
29
30
31
32
33
34
35
36
37

38
39 **Ethics Approval** This research project was approved by the Research Ethics Committee
40 of the Vitalité Health Network (first approval 23-12-2009, amendment approved on 26-5-
41 2016).
42
43
44

45
46 **Funding** S.E. is the recipient of the New Brunswick Health Research Foundation and
47 Canadian Institutes for Health Research-Strategy for Patient Oriented Research-Maritime
48 SPOR SUPPORT Unit Post-Doctoral Fellowship award.
49
50
51
52
53
54
55
56
57
58
59
60

What is already known on this topic?

- Use of intravenous fluids (i.e. crystalloids and colloids) prior to and/or during anesthesia is a common strategy to prevent maternal hypotension during caesarean sections.
- No study has examined the impact of colloids – or colloids plus crystalloids combination – on excess weight loss (EWL) among newborns.
- Published literature provides conflicting evidence of association between IV fluids – specifically crystalloids – and EWL.

What this study adds?

- Weight loss difference and the risk of EWL were similar with colloids plus crystalloids and crystalloids only among women undergoing caesarean delivery.
- No dose-response relationship observed between colloids, crystalloids or total IV fluids and an increased risk of EWL.
- Primary and sensitivity analyses suggest that both therapeutic options can be considered as safe during caesarean sections.

References

- 1 Cyna AM, Andrew M, Emmett RS, *et al.* Techniques for preventing hypotension during spinal anaesthesia for caesarean section. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd 2006.
doi:10.1002/14651858.CD002251.pub2
- 2 Mercier FJ, Diemunsch P, Ducloy-Bouthors AS, *et al.* 6% Hydroxyethyl starch (130/0.4) vs Ringer's lactate preloading before spinal anaesthesia for Caesarean delivery: The randomized, double-blind, multicentre CAESAR trial. *Br J Anaesth* 2014;**113**:459–67. doi:10.1093/bja/aeu103
- 3 Teoh WHL, Westphal M, Kampmeier TG. Update on volume therapy in obstetrics. *Best Pract Res Clin Anaesthesiol* 2014;**28**:297–303. doi:10.1016/j.bpa.2014.07.004
- 4 Mercier FJ. Cesarean delivery fluid management. *Curr Opin Anaesthesiol* 2012;**25**:286–91. doi:10.1097/ACO.0b013e3283530dab
- 5 Ripolles Melchor J, Espinosa, Martinez Hurtado E, *et al.* Colloids versus crystalloids in the prevention of hypotension induced by spinal anesthesia in elective cesarean section. A systematic review and meta-analysis. *Minerva Anesthesiol.* 2015;**81**:1019–30.
- 6 Flaherman VJ, Schaefer EW, Kuzniewicz MW, *et al.* Early weight loss nomograms for exclusively breastfed newborns. *Pediatrics* 2015;**135**:16–23.
doi:10.1542/peds.2014-1532
- 7 Miller JR, Flaherman VJ, Schaefer EW, *et al.* Early weight loss nomograms for formula fed newborns. *Hosp Pediatr* 2015;**5**:263–8. doi:10.1542/hpeds.2014-0143
- 8 Moritz ML, Manole MD, Bogen DL, *et al.* Breastfeeding-associated

hypertremia: are we missing the diagnosis? *Pediatrics* 2005;**116**:e343–7.

doi:10.1542/peds.2004-2647

- 9 Escobar GJ, V.M G, Armstrong MA, *et al.* Rehospitalization for neonatal
10 dehydration: A nested case-control study. *Arch Pediatr Adolesc Med*
11 2002;**156**:155–61. doi:poa10396 [pii]
12
13
14
15
16 10 Van Amerongen RH, Moretta AC, Gaeta TJ. Severe hypertremic dehydration
17 and death in a breast-fed infant. *Pediatr Emerg Care* 2001;**17**:175–80.
18
19
20
21
22
23 11 Chantry CJ, Nommsen-Rivers LA, Peerson JM, *et al.* Excess Weight Loss in First-
24 Born Breastfed Newborns Relates to Maternal Intrapartum Fluid Balance.
25
26
27
28
29
30 12 Noel-Weiss J, Woodend a K, Peterson WE, *et al.* An observational study of
31 associations among maternal fluids during parturition, neonatal output, and
32
33
34
35
36
37
38
39 13 Hirth R, Weitkamp T, Dwivedi A. Maternal Intravenous Fluids and infant weight.
40
41
42
43
44
45
46
47
48
49
50
51 15 Dewey KG, Nommsen-rivers LA, Heinig MJ, *et al.* Risk Factors for Suboptimal
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 16 Firth D. Bias Reduction of Maximum-Likelihood-Estimates. *Biometrika* 1993;**80**:27–38. doi:10.1093/biomet/80.1.27
- 17 Tawia S, Mcguire L. Early weight loss and weight gain in healthy , full-term , exclusively-breastfed infants. *Breastfeed Rev* 2014;**22**:31–42.
- 18 Mezzacappa MA, Ferreira BG. Excessive weight loss in exclusively breastfed full-term newborns in a Baby-Friendly Hospital. *Rev Paul Pediatr (English Ed)* 2016;**34**:281–6. doi:10.1016/j.rppede.2016.03.003
- 19 Moen V, Brudin L, Rundgren M, *et al.* Hyponatremia complicating labour--rare or unrecognised? A prospective observational study. *BJOG* 2009;**116**:552–61. doi:10.1111/j.1471-0528.2008.02063.x
- 20 Lamp JM, Macke JK. Relationships among intrapartum maternal fluid intake, birth type, neonatal output, and neonatal weight loss during the first 48 hours after birth. *J Obstet Gynecol Neonatal Nurs* 2010;**39**:169–77. doi:10.1111/j.1552-6909.2010.01106.x
- 21 Watson J, Hodnett E, Armson BA, *et al.* A randomized controlled trial of the effect of intrapartum intravenous fluid management on breastfed newborn weight loss. *J Obstet Gynecol Neonatal Nurs* 2012;**41**:24–32. doi:10.1111/j.1552-6909.2011.01321.x
- 22 Grossman X, Chaudhuri JH, Feldman-Winter L, *et al.* Neonatal Weight Loss at a US Baby-Friendly Hospital. *J Acad Nutr Diet* 2012;**112**:410–3. doi:10.1016/j.jada.2011.10.024
- 23 Thulier DJ. Maternal hydration and infant weight: A case-control study in breastfeeding infants delivered by cesarean section. *ProQuest Diss Theses*

- 2013;:126.http://digitalcommons.uri.edu/oa_diss
- 24 Zetterström R. Excessive fluid intake before and during delivery causing water intoxication in the mother and her offspring. *Acta Paediatr* 2007;**91**:867–8. doi:10.1111/j.1651-2227.2002.tb02846.x
- 25 Cotterman KJ. Reverse Pressure Softening: A Simple Tool to Prepare Areola for Easier Latching During Engorgement. *J Hum Lact* 2004;**20**:227–37. doi:10.1177/0890334404264224
- 26 Kujawa-Myles S, Noel-Weiss J, Dunn S, *et al*. Maternal intravenous fluids and postpartum breast changes: a pilot observational study. *Int Breastfeed J* 2015;**10**:18. doi:10.1186/s13006-015-0043-8
- 27 Lyons G. Epidural is an outmoded form of regional anaesthesia for elective caesarean section. Proposer. *Int J Obstet Anesth* 1995;**4**:34–6.
- 28 Robson SC, Boys RJ, Rodeck C, *et al*. Maternal and fetal haemodynamic effects of spinal and extradural anaesthesia for elective caesarean section. *Br J Anaesth* 1992;**68**:54–9.
- 29 Roberts SW, Leveno KJ, Sidawi JE, *et al*. Fetal acidemia associated with regional anesthesia for elective cesarean delivery. *Obstet Gynecol* 1995;**85**:79–83.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Cohort selection flow diagram

Table I. Characteristics of Mothers-Infants Pairs According to Intrapartum Colloids and Crystalloids Exposure for Caesarean Section

	Missing data	Colloids plus Crystalloids	Crystalloids only
	No. (%)	No. of deliveries (%)	
		176 (22.0)	625 (78.0)
Gestational and maternal variables			
Maternal age in years (Mean ± SD)	0 (0)	29.7 ±4.9	29.2 ±5.2
≤35		155 (88.1)	547 (87.5)
>35		21 (11.9)	78 (12.5)
Gravida	2 (0.2)		
1		89 (50.9)	285 (45.7)
2-4		79 (45.1)	311 (49.8)
≥5		7 (4.0)	28 (4.5)
Para	2 (0.2)		
0		104 (59.4)	363 (58.2)
1		55 (31.4)	200 (32.0)
≥2		16 (9.2)	61 (9.8)
Abortus	2 (0.2)		
0		135 (77.1)	439 (70.4)
1		33 (18.9)	128 (20.5)
≥2		7 (4.0)	57 (9.1)
Cigarette smoking	2 (0.2)	21 (11.9)	105 (16.9)
Alcohol drinking	4 (0.5)	14 (8.0)	85 (13.7)
Drug use	4 (0.5)	6 (3.4)	24 (3.9)
Gestational diabetes	0 (0)	5 (2.8)	38 (6.1)
Hypertension during pregnancy	0 (0)	9 (5.1)	41 (6.6)
Pre-eclampsia	0 (0)	11 (6.3)	29 (4.6)
Epidural before caesarean section	0 (0)	53 (30.1)	272 (43.5)
Elective caesarean section	4 (0.5)	73 (41.7)	233 (37.5)
Infant related variables			
Birth weight in grams (Mean ± SD)	12 (1.5)	3383 (±572)	3449 (±544)
Gestational age in weeks (Mean ± SD)	12 (1.5)	38.6 (±1.4)	39.0 (±1.6)
Preterm delivery	12 (1.5)	19 (11.1)	43 (7.0)
Low Apgar score (< 7) at 1 min	14 (1.7)	8 (4.7)	34 (5.5)
Fever during hospitalization	14 (1.7)	4 (2.3)	11 (1.8)
Phototherapy on day 1	13 (1.6)	5 (2.9)	9 (1.5)
Phototherapy on day 2	13 (1.6)	9 (5.2)	21 (3.4)
Phototherapy on day 3	14 (1.7)	18 (10.5)	36 (5.9)
Breastfeeding during hospitalization	15 (1.9)	46 (26.9)	290 (47.2)
Urine during day 1	15 (1.9)		
0		29 (17.0)	56 (9.1)
1-2		64 (37.4)	239 (38.9)

3-5		66 (38.6)	274 (44.5)
≥6		12 (7.0)	46 (7.5)
Urine during day 2	17 (2.1)		
0		1 (0.6)	5 (0.8)
1-2		28 (16.5)	150 (24.4)
3-5		112 (65.9)	355 (57.8)
≥6		29 (17.0)	104 (17.0)
Urine during day 3	73 (9.1)		
0		0 (0.0)	3 (0.5)
1-2		32 (19.5)	115 (20.4)
3-5		93 (56.7)	326 (57.8)
≥6		39 (23.8)	120 (21.3)
Stools during day 1	15 (1.9)		
0		21 (12.3)	62 (10.1)
1-2		65 (38.0)	238 (38.7)
3-5		81 (47.4)	292 (47.5)
≥6		4 (2.3)	23 (3.7)
Stools during day 2	17 (2.1)		
0		5 (2.9)	23 (3.7)
1-2		44 (25.9)	218 (35.5)
3-5		102 (60.0)	334 (54.4)
≥6		19 (11.2)	39 (6.4)
Stools during day 3	73 (9.1)		
0		5 (3.1)	21 (3.7)
1-2		63 (38.4)	193 (34.2)
3-5		84 (51.2)	312 (55.3)
≥6		12 (7.3)	38 (6.8)
Colloids doses in ml*	1 (0.1)		
0		0 (0)	625 (78.1)
>0-500		47 (5.9)	-
>500		128 (16.0)	-
Crystalloids doses in ml	26 (3.2)		
0		16 (2.1)*	0 (0)
>0-1000		54 (7.0)	168 (21.7)
>1000-2000		84 (10.8)	320 (41.3)
>2000		18 (2.3)	115 (14.8)
Total IV fluid doses in ml	26 (3.2)		
>0-1000		22 (2.8)	168 (21.7)
>1000-2000		102 (13.2)	320 (41.3)
>2000-3000		42 (5.4)	108 (13.9)
>3000		6 (0.8)	7 (0.9)

*Deliveries with missing data on crystalloids doses but available data on colloids doses (16 patients' records) were included in the Colloids plus Crystalloids group in the statistical analysis.

Table II. Beta Coefficients and 95% Confidence Intervals of the Linear Regression Models for Difference in Weight at 24, 48, and 72 Hours Postpartum According to Maternal Intrapartum Colloids and Crystalloids Exposure

	Difference in weight in grams (β and 95% CI)					
	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	<i>Model 1 (crude)</i>	<i>Model 3</i>	<i>Model 1 (crude)</i>	<i>Model 3</i>	<i>Model 1 (crude)</i>	<i>Model 3</i>
Colloids plus Crystalloids	-0.6 (-12.6, 11.4)	-5.2 (-17.5, 7.0)	-0.4 (-15.9, 15.0)	-10.8 (-26.1, 4.5)	-5.4 (-28.2, 17.4)	-9.2 (-32.0, 13.7)
Crystalloids only	Reference	Reference	Reference	Reference	Reference	Reference
Colloids doses in ml (vs 0)						
>0-500	-5.8 (-27.9, 16.4)	-9.3 (-31.3, 12.7)	-3.1 (-31.9, 25.7)	-9.5 (-37.3, 18.3)	-11.0 (-55.5, 33.4)	-13.1 (-56.8, 30.6)
>500	-0.4 (-14.6, 13.8)	-5.8 (-20.1, 8.5)	1.6 (-16.8, 20.1)	-9.8 (-27.8, 8.1)	-8.2 (-35.2, 18.8)	-7.9 (-34.5, 18.7)
Crystalloids doses in ml (vs 0)						
>0-1000	4.2 (-33.0, 41.4)	-2.6 (-40.9, 35.7)	5.0 (-43.3, 53.3)	13.9 (-34.3, 62.1)	-0.03 (-73.6, 73.5)	39.8 (-35.6, 115.1)
>1000-2000	2.9 (-33.9, 39.6)	-1.5 (-39.4, 36.4)	9.5 (-38.2, 57.2)	21.9 (-25.8, 69.6)	-7.6 (-80.1, 64.9)	39.5 (-35.1, 114.1)
>2000	-0.5 (-38.8, 37.8)	-6.8 (-46.0, 32.4)	2.8 (-46.9, 52.6)	9.8 (-39.4, 59.1)	-21.6 (-97.2, 53.9)	15.2 (-61.5, 91.9)
Total IV fluid doses in ml: (vs >0-1000)						
>1000-2000	-4.5 (-16.6, 7.6)	-2.9 (-15.0, 9.2)	4.3 (-11.5, 20.1)	8.1 (-7.1, 23.3)	-7.4 (-31.7, 17.0)	3.5 (-20.2, 27.3)
>2000-3000	-1.6 (-16.9, 13.7)	-2.7 (-17.8, 12.3)	0.8 (-19.1, 20.7)	-0.3 (-19.2, 18.6)	-24.8 (-54.6, 4.9)	-22.1 (-50.9, 6.6)
>3000	-26.7 (-67.7, 14.3)	-27.3 (-66.9, 12.2)	-14.4 (-38.9, 67.7)	-6.4 (-43.4, 56.2)	-3.9 (-81.1, 73.3)	-0.6 (-73.0, 71.8)

The regression coefficient represents the estimated difference in weight since birth

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

Model 3 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, election to have a caesarean section, Apgar score, breastfeeding, number of stools, number of urine, presence of fever and phototherapy.

Table III. Adjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) for Excess Weight Loss (>7%) According to Type of Intrapartum IV Fluid Received by Mothers for Caesarean Section

	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)</i>	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>
Colloids plus Crystalloids	0.9 (0.2–3.2)	1.0 (0.3–3.3)	0.9 (0.6–1.3)	1.0 (0.7–1.5)	1.3 (0.9–2.0)	1.4 (0.9–2.2)
Crystalloids only	Reference	Reference	Reference	Reference	Reference	Reference
Maternal age in years	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (>0.9–1.1<)	1.0 (>0.9–1.0)	1.0 (>0.9–1.1)	1.0 (>0.9–1.1)
Gravida	0.9 (0.6–1.4)	0.3 (0.1–>99)	0.9 (0.8–1.0)	0.7 (0.2–2.5)	0.8 (0.7–0.9)	8.8 (0.7–>99)
Para	0.9 (0.4–1.8)	3.8 (<0.1–24.6)	0.8 (0.7–1.0)	1.2 (0.3–4.7)	0.7 (0.5–0.8)	0.1 (<0.1–0.8)
Abortus	0.9 (0.4–1.8)	3.3 (<0.1–19.7)	0.9 (0.7–1.1)	1.3 (0.4–5.0)	0.8 (0.6–1.0)	0.1 (<0.1–1.2)
Gestational age	1.1 (0.8–1.6)	0.9 (0.6–1.4)	1.1 (1.0–1.3)	1.0 (0.9–1.2)	1.1 (1.0–1.2)	0.9 (0.8–1.1)
Cigarette smoking	2.8 (0.9–8.3)	1.9 (0.5–5.9)	0.7 (0.5–1.1)	0.8 (0.5–1.3)	0.5 (0.3–0.7)	0.7 (0.4–1.2)
Drug use	4.2 (0.9–19.7)	2.8 (0.4–13.6)	0.7 (0.3–1.5)	0.6 (0.3–1.6)	1.1 (0.5–2.6)	1.3 (0.5–3.4)
Alcohol drinking	1.1 (0.2–4.8)	1.0 (0.2–3.7)	1.1 (0.7–1.8)	1.1 (0.7–1.7)	1.2 (0.7–1.9)	1.1 (0.7–2.0)
Hypertension during pregnancy	0.5 (<0.1–3.7)	0.2 (<0.1–2.6)	0.5 (0.3–1.0)	0.6 (0.3–1.3)	0.7 (0.4–1.3)	0.5 (0.2–1.1)
Gestational diabetes	1.3 (0.2–10.1)	1.6 (0.2–7.3)	1.2 (0.6–2.2)	1.4 (0.7–2.8)	0.7 (0.4–1.5)	1.2 (0.5–3.0)
Pre-eclampsia	1.4 (0.2–10.7)	3.8 (0.3–22.8)	0.4 (0.2–0.8)	0.6 (0.2–1.4)	1.1 (0.5–2.0)	1.5 (0.7–3.5)
Epidural before caesarean section	1.3 (0.5–3.6)	0.9 (0.2–3.6)	1.3 (0.9–1.6)	1.5 (1.0–2.4)	0.9 (0.6–1.2)	0.9 (0.5–1.4)
Elective caesarean section	0.6 (0.2–1.8)	0.6 (0.2–2.6)	1.2 (0.9–1.6)	1.7 (1.1–2.6)	1.3 (1.0–1.9)	1.8 (1.1–2.9)
Apgar score	1.4 (0.6–3.2)	1.2 (0.8–3.4)	1.2 (1.0–1.3)	1.2 (1.0–1.4)	1.1 (1.0–1.2)	1.1 (0.9–1.2)
Fever during hospitalization	1.6 (<0.1–13.2)	1.5 (<0.1–13.6)	2.6 (0.9–7.8)	3.3 (1.1–10.4)	0.8 (0.3–2.3)	1.0 (0.3–3.1)
Breastfeeding during hospitalization	0.7 (0.2–2.0)	0.9 (0.3–2.7)	1.3 (1.0–1.8)	1.1 (0.8–1.5)	1.6 (1.1–2.1)	1.5 (1.0–2.2)

Phototherapy on day 1	4.0 (0.5–32.9)	7.7 (0.7–46.1)	1.1 (0.4–3.1)	1.4 (0.4–4.8)	0.3 (0.1–1.1)	0.3 (0.1–1.2)
Phototherapy on day 2	N/A	N/A	1.1 (0.5–2.3)	1.6 (0.7–3.9)	0.9 (0.4–2.0)	1.7 (0.7–4.4)
Phototherapy on day 3	N/A	N/A	N/A	N/A	0.7 (0.4–1.3)	0.8 (0.4–1.6)
Urine during day 1	1.0 (0.8–1.4)	0.8 (0.6–1.2)	1.0 (0.9–1.1)	1.0 (0.9–1.2)	1.0 (0.9–1.1)	1.1 (1.0–1.2)
Urine during day 2	N/A	N/A	0.8 (0.8–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.0)
Urine during day 3	N/A	N/A	N/A	N/A	0.8 (0.7–0.9)	0.9 (0.8–1.0)
Stools during day 1	1.5 (1.1–2.1)	1.6 (1.1–2.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.0 (0.8–1.1)
Stools during day 2	N/A	N/A	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)
Stools during day 3	N/A	N/A	N/A	N/A	0.7 (0.6–0.8)	0.7 (0.6–0.8)

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

N/A: not applicable

*Firth penalized maximum likelihood estimation method was used for quasi-complete separation

Table IV. Crude and Adjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) for Excess Weight Loss (>7%) According to Doses of Intrapartum IV Fluid Received by Mothers for Caesarean Section

24 hours postpartum				48 hours postpartum			72 hours postpartum		
No. cases (%)	Model 1 (crude)OR (95% CI)*	Model 3 Adjusted OR (95% CI)*	No. cases (%)	Model 1 (crude)OR (95% CI)	Model 3 Adjusted OR (95% CI)	No. cases (%)	Model 1 (crude)OR (95% CI)	Model 3 Adjusted OR (95% CI)*	

Regression models for type-specific doses of IV fluid

Colloids doses (in ml)									
0	12 (2.0)	Reference	Reference	252 (41.9)	Reference	Reference	260 (53.8)	Reference	Reference
>0-500	2 (4.4)	3.3 (0.6–11.8)	2.7 (0.4–11.5)	17 (37.0)	0.9 (0.5–1.7)	1.0 (0.5–2.1)	20 (55.6)	1.1 (0.6–2.3)	1.3 (0.6–2.9)
>500	1 (0.8)	0.7 (0.1–2.8)	0.7 (0.1–3.1)	48 (39.7)	0.9 (0.6–1.4)	1.0 (0.6–1.5)	70 (62.5)	1.4 (0.9–2.1)	1.3 (0.8–2.1)
Crystalloids doses (in ml)									
0	0 (0.0)	Reference	Reference	6 (37.5)	Reference	Reference	9 (75.0)	Reference	Reference
>0-1000	3 (1.4)	N/A	N/A	92 (43.0)	1.1 (0.4–3.4)	0.8 (0.2–2.6)	93 (54.1)	0.5 (0.1–1.9)	0.2 (<0.1–1.1)
>1000-2000	10 (2.6)	N/A	N/A	156 (40.1)	1.0 (0.3–3.0)	0.6 (0.2–2.0)	179 (56.7)	0.5 (0.1–2.1)	0.2 (<0.1–0.9)
>2000	1 (0.8)	N/A	N/A	56 (44.8)	1.2 (0.4–3.8)	0.9 (0.2–3.0)	61 (55.0)	0.5 (0.1–2.1)	0.3 (<0.1–1.2)

Regression models for total doses of IV fluid

Total IV fluid doses (in ml)									
>0-1000	3 (1.7)	Reference	Reference	82 (44.8)	Reference	Reference	81 (55.5)	Reference	Reference
>1000-2000	8 (2.0)	1.1 (0.3–4.4)	1.1 (0.3–4.5)	161 (39.3)	0.8 (0.6–1.1)	0.7 (0.5–1.0)	183 (56.0)	1.0 (0.7–1.5)	0.8 (0.5–1.2)
>2000-3000	3 (2.2)	1.3 (0.3–6.3)	1.2 (0.2–6.1)	64 (45.7)	1.0 (0.7–1.6)	1.0 (0.6–1.6)	71 (55.9)	1.0 (0.6–1.6)	0.9 (0.5–1.6)
>3000	0 (0.0)	N/A	N/A	3 (27.3)	0.5 (0.1–1.8)	0.5 (0.1–2.0)	7 (63.6)	1.4 (0.4–5.0)	1.1 (0.3–4.6)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

Model 3 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, election to have a caesarean section, Apgar score, breastfeeding, number of stools, number of urine, presence of fever and phototherapy.

N/A: not applicable

Firth penalized maximum likelihood estimation method was used for quasi-complete separation

Figures legend

Figure 1. Cohort selection flow diagram

BMJ Paediatrics Open

Intrapartum intravenous fluids for caesarean delivery and newborn weight loss: a retrospective cohort study

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2017-000070.R1
Article Type:	Original article
Date Submitted by the Author:	11-Jul-2017
Complete List of Authors:	Eltonsy, Sherif; Centre de formation médicale du Nouveau-Brunswick Blinn, Alain; Université de Sherbrooke, Department of family medicine Sonier, Brigitte; Research Centre, Vitalité Health Network Deroche, Steven; Université de Sherbrooke Faculté de médecine et des sciences de la santé Mulaja, Aubin; Université de Sherbrooke Faculté de médecine et des sciences de la santé Hynes, William; Université de Sherbrooke Faculté de médecine et des sciences de la santé Barrieau, André; Université de Sherbrooke Faculté de médecine et des sciences de la santé Belanger, Mathieu; Centre de formation médicale du Nouveau-Brunswick; Université de Sherbrooke Faculté de médecine et des sciences de la santé
Keywords:	Epidemiology, Neonatology, Therapeutics, Anaesthetics

SCHOLARONE™
Manuscripts

**Intrapartum intravenous fluids for caesarean delivery and newborn weight loss: a
retrospective cohort study**

Sherif Eltonsy PhD^{1,2}, Alain Blinn MD^{3,4}, Brigitte Sonier PhD⁵, Steven DeRoche MD^{3,4},
Aubin Mulaja MD^{3,4}, William Hynes MD^{3,4}, André Barrieau MD^{3,4}, Mathieu
Bélanger PhD^{1,3,4,5*}

¹ Centre de formation médicale du Nouveau-Brunswick (Moncton, Canada)

² The Maritime SPOR SUPPORT Unit (MSSU) (Moncton, Canada)

³ Department of family medicine, Université de Sherbrooke (Sherbrooke, Canada)

⁴ Dieppe Family Medicine Unit (Dieppe, Canada)

⁵ Research Centre, Vitalité Health Network (Moncton, Canada)

***Corresponding author:** Mathieu Bélanger, PhD
Centre de formation médicale du Nouveau-Brunswick
Pavillon J.-Raymond-Frenette
15, rue des Aboiteaux
Moncton, NB Canada E1A 3E9
+1 506 863 2221 (phone)
+1 506 863 2284 (fax)
mathieu.f.belanger@usherbrooke.ca

Word count: 2825

Keywords: Birth weight, Weight loss, Colloids, Crystalloids, Caesarean section.

ABSTRACT

Objective: To examine weight loss (WL) and excess weight loss (EWL) among newborns of caesarean delivery, comparing colloids plus crystalloids versus crystalloids only. Also, to examine different doses of intrapartum intravenous (IV) fluids on WL and EWL.

Design: Comparative safety retrospective cohort study.

Setting: University teaching hospital, Moncton, Canada.

Patients: Mothers exposed to IV fluids with caesarean delivery between 2008 and 2016.

Interventions: Exposure to colloids plus crystalloids was compared to crystalloids only, and dose-response analyses were performed for colloids, crystalloids and total IV fluids doses. Linear and logistic regression models were used, adjusting for potential confounders.

Main outcome measures: Infants' WL was measured at days 1, 2 and 3 postpartum, and EWL defined as loss of > 7% of birth weight.

Results: From 801 mother-infant pairs, 176 were exposed to colloids plus crystalloids and 625 were exposed to crystalloids only (overall mean birth weight = 3416 g, EWL = 2%, 41.4% and 55.5% on days 1, 2 and 3 respectively). No significant difference in newborns' WL was observed on any of the days assessed. Adjusted odds ratio (95% CI) of EWL was 1.0 (0.3–3.3) at 24 hours, 1.0 (0.7–1.5) at 48 hours and 1.4 (0.9–2.2) at 72 hours. No dose-response relationship was detected with type-specific and total IV fluids exposures.

1
2
3 **Conclusions:** The risk of EWL was similar with colloids plus crystalloids and
4
5 crystalloids only, suggesting that both therapeutic options can be considered during
6
7 caesarean delivery. The absence of dose-response relationships adds confirmatory
8
9 evidence to the IV fluids safety profiles.
10
11

12 **Keywords:** Birth weight, Weight loss, Colloids, Crystalloids, Caesarean section.
13
14
15
16
17
18
19

20 INTRODUCTION

21
22 Hypotension is the most significant adverse effect in women undergoing spinal anesthesia
23
24 for caesarean delivery, affecting on average 70% of pregnant women.[1,2] The
25
26 administration of intravenous (IV) fluids (i.e. crystalloids and colloids) prior to and/or
27
28 during anesthesia represents one of the most common strategies to prevent maternal
29
30 hypotension.[1] Among the IV fluids, crystalloid solutions are the most frequently used,
31
32 with normal saline (NS) and Ringer's lactate (RL) as the most common choices.[3]
33
34 Colloids are frequently used nowadays for several reasons. Preloading with crystalloids
35
36 alone have shown poor effectiveness in decreasing hypotension.[3] While crystalloids co-
37
38 loading is considered superior, variable effectiveness were reported.[1,3] Systematic
39
40 reviews and meta-analyses indicate that pre- or co-loading with colloids – specifically
41
42 hydroxyethyl starches (HES) – is superior to crystalloids alone, with volumes larger than
43
44 500 ml offering no significant additional benefits.[1–5] Current practice advocate
45
46 combining colloids and crystalloids solutions rather than colloids alone.[2]
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 While colloids are becoming an increasingly used choice as IV fluid in pregnant women
4
5
6 undergoing caesarean section, no study has examined the impact of colloids – or colloids
7
8 plus crystalloids combination – on excess weight loss (EWL) among newborns. Although
9
10 normal physiological weight loss occurs after delivery,[6,7] EWL (i.e. loss of more than
11
12 7-10% of birth weight) is considered a complication which increases the risk of
13
14 hyperbilirubinemia, hypernatremic dehydration, hospitalizations and long-term
15
16 morbidities.[8–10] Recent literature reports growing evidence of positive association
17
18 between IV fluids – specifically crystalloids – and EWL (between 7% to 10%),[11–14]
19
20 and it remains unclear whether different IV fluid combinations present similar safety
21
22 profiles. The primary objective of the current study was to examine amount of weight
23
24 loss and EWL among newborns of caesarean delivery, comparing colloids plus
25
26 crystalloids intrapartum IV fluids versus crystalloids only. The secondary objective was
27
28 to examine the association between different doses of intrapartum IV fluids and newborn
29
30 weight loss, as well as EWL.
31
32
33
34
35
36
37
38

39 **METHODS**

40 **Study Design**

41
42 A population-based retrospective cohort design was used. The cohort was selected from
43
44 mothers hospitalized at the Dr. George-L.-Dumont University Hospital Centre (New
45
46 Brunswick, Canada) between April 2008 and June 2016. The average hospital stay for
47
48 mothers after caesarean deliveries in New Brunswick is 72 hours. Trained medical staff
49
50 extracted the information from the hospital medical records of mothers undergoing
51
52 caesarean deliveries and their linked newborns' files. Data collection was performed on
53
54
55
56
57
58
59
60

two periods for logistical and sample size reasons; (1) records from all (n = 320) caesarean deliveries between April 2008 and January 2010 and (2) a random sample of 500 caesarean deliveries between February 2010 and June 2016 were retained. Performing separate primary analysis for the two periods did not show major differences in results.

Cohort Selection

The cohort inclusion criteria were: (1) a pregnancy with a recorded caesarean delivery between April 1, 2008 and June 31, 2016; (2) recorded singleton live birth; (3) maternal age at the beginning of pregnancy of 15-45 years; (4) gestational duration of 30-42 weeks; and (5) exposure to colloids or crystalloids IV fluids before caesarean delivery.

The exclusion criteria were: (1) missing data on IV fluids administration in addition to several other important variables and (2) infants with feeding difficulties leading to unsuccessful oral feeding (neither breastfeeding nor formula) during the hospitalization period (i.e nil per os [NPO]).

Weight Loss and EWL

From the infants' medical records, we extracted information on birth weight and infants' weight at 24, 48 and 72 hours. EWL was defined as loss of > 7% of birth weight, calculated at 24, 48 and 72 hours postpartum.[6,7,15]

IV Fluids Exposure

Colloids (Voluven®, Pentaspan® and others/non-specified) plus crystalloids (RL, NS and others/non specified) use was defined as the maternal intrapartum exposure to both colloids and crystalloids IV fluids for caesarean delivery. Crystalloids use (RL, NS and others/non-specified) was defined as the maternal intrapartum exposure to crystalloids

only. Being “non-specified” refers to cases where an indicator was present that a colloid or a crystalloid was administered, but no detail on the specific type was recorded. The doses of colloids were categorized as: 0, > 0-500, > 500 ml and doses of crystalloids were categorized as: 0, > 0-1000, > 1000-2000, > 2000 ml. We calculated the total doses of IV fluids; categorized into: 0-1000, > 1000-2000, > 2000-3000, > 3000ml.

Confounding Variables

Two classes of potential risk factors were included in the analysis. First, gestational and maternal variables, including: maternal age in years at delivery, number of pregnancies, number of viable births, number of lost pregnancies, gestational diabetes (yes/no), hypertension during pregnancy (yes/no), pre-eclampsia (yes/no), cigarette smoking during pregnancy (yes/no), alcohol drinking during pregnancy (yes/no), drug use during pregnancy (yes/no), epidural before caesarean section (yes/no), and elective caesarean section (yes/no). Second, infant related variables, including: gestational age in weeks, Apgar score, fever during hospitalization (yes/no), exclusive breastfeeding during hospitalization (i.e. we excluded only formula and breastfeeding-formula combined) (yes/no), phototherapy on days 1 (yes/no), 2 (yes/no) and 3 (yes/no), number of urine on each of day 1, 2 and 3, and number of stools on each of day 1, 2 and 3.

Statistical Analysis

The descriptive statistics for the characteristics of the mothers-infants pairs were calculated and compared between groups. Four regression forms were employed, two for the difference in weight according to types and doses of IV fluids, and two for EWL according to types and doses of IV fluids. We compared the amount of weight lost by infants in both groups (as absolute measure in grams) at 24, 48 and 72 hours postpartum

1
2
3 using crude and adjusted linear regressions, with crystalloids only users as reference
4
5 group. Three regression models were constructed: *Model 1* (crude, i.e. single univariate
6
7 regression model), *Model 2* (adjusted for maternal age, gestational diabetes, hypertension
8
9 during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age,
10
11 pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean
12
13 section, and elective caesarean section) and *Model 3* (adjusted for the variables in Model
14
15 2, in addition to Apgar score, exclusive breastfeeding, number of stools, number of urine,
16
17 presence of fever and phototherapy). The purpose of this methodology is that the
18
19 additional variables in Model 3 were measured during the postpartum period and not at
20
21 baseline, and through them, the effect of IV fluids on weight loss could be mediated.
22
23
24
25
26
27 Additional regression models for colloids and crystalloids doses were used to examine
28
29 trends and dose-response relationships with newborn weight loss, similarly with the total
30
31 IV fluid doses. Logistic regression models were used to estimate crude and adjusted odds
32
33 ratios (ORs) and 95% confidence intervals (CIs) for EWL, with adjustment for potential
34
35 confounders as listed above. Firth penalized maximum likelihood estimation method was
36
37 used whenever quasi-complete separation in data was detected in logistic regression
38
39 models.[16]
40
41
42

43 **Sensitivity Analysis**

44
45 First, the maximum physiological limits of weight loss for newborns are
46
47 controversial,[17,18] thus, we reanalyzed our data using EWL defined as (1) loss of > 5%
48
49 and (2) loss of > 10% of birth weight. Second, suboptimal breastfeeding and delayed
50
51 onset of lactogenesis can lead to EWL.[11,15] Therefore, we tested its potential effect
52
53 using 2 different techniques; (1) performed all analyses among the subgroup of breastfed
54
55
56
57
58
59
60

1
2
3 newborns only and (2) excluded exclusive breastfeeding as potential confounder from
4
5 Model 3. Using a type I error of 0.05 and 80% power, a sample size of 818 mother-
6
7 infants pairs was estimated to be sufficient to detect a weight loss difference of 10%
8
9 between the group exposed to colloids plus crystalloids versus the group exposed to
10
11 crystalloids only. All statistical analyses were conducted using SAS software, version 9.3
12
13 (SAS Institute Inc., Cary, NC). This study was approved by the Research Ethics
14
15 Committee of the Vitalité Health Network.
16
17
18
19
20
21

22 RESULTS

23
24 A total of 801 mother-infant pairs fulfilled our inclusion and exclusion criteria (see
25
26 Figure 1 for the selection process). From these, 176 mother-infant pairs were exposed to
27
28 colloids plus crystalloids intrapartum and 625 were exposed to crystalloids only. Among
29
30 the colloids plus crystalloids group, 103 (58.5%) were exposed to Voluven®, 22 (12.5%)
31
32 to Pentaspan®, and 51 (29%) to other colloids or non-specified. For crystalloids, 546
33
34 (87.3%) were exposed to RL only, 44 (7.1%) to RL and NS, and 35 (5.6%) to other
35
36 crystalloids or non-specified. The most frequently used doses of colloids and crystalloids
37
38 were > 500 ml and >1000-2000 ml, respectively. Overall, the mean birth weight for the
39
40 newborns was 3416 g. During the hospitalization period, EWL of > 7% was detected in
41
42 15 infants (2%) at 24 hours, 318 infants (41.4%) at 48 hours, 351 infants (55.5%) at 72
43
44 hours, and EWL of > 10% was detected in 3 infants (0.4%) at 24 hours, 17 infants (2.2%)
45
46 at 48 hours and 100 infants (15.8%) at 72 hours.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In both groups, most women were ≤ 35 years of age, with approximately 1 to 4 gravidity,
4
5 0 to 1 parity and 0 to 1 abortus (Table I). However, based on crude observations, women
6
7 exposed to crystalloids only were more likely to have suffered from gestational diabetes,
8
9 to have been exposed to epidural before caesarean section, to report cigarette smoking
10
11 and alcohol drinking. The incidence of preterm deliveries and phototherapy on day 3
12
13 were higher among infants in the colloids plus crystalloids group, while exclusive
14
15 breastfeeding during hospitalization was more successful in the crystalloids only group.
16
17
18
19
20
21

22 **Differences in Weight**

23
24 We observed no significant difference in newborns' weight loss between women exposed
25
26 to colloids plus crystalloids compared to crystalloids only intrapartum on any of the three
27
28 days assessed (Table II). Moreover, none of the doses of colloids, crystalloids or total IV
29
30 fluids was found to be associated with a significant difference in weight loss, nor with a
31
32 trend of increased or decreased risk over time. We obtained similar estimates for Models
33
34 2 and 3 (only results from Model 3 are presented, others are available upon request).
35
36
37
38
39
40

41 **Differences in EWL by Group**

42
43 We observed no significant difference in the risk of EWL ($>7\%$) at 24 hours (adjusted
44
45 OR: 1.0; 95% CI: 0.3–3.3), 48 hours (adjusted OR: 1.0; 95% CI: 0.7–1.5) or 72 hours
46
47 (adjusted OR: 1.4; 95% CI: 0.9–2.2) (Table III). Elective caesarean section was
48
49 associated with a significant increased risk of EWL at 48 hours (adjusted OR: 1.7; 95%
50
51 CI: 1.1–2.6) and at 72 hours (adjusted OR: 1.8; 95% CI: 1.1–2.9). Number of stools
52
53 measured on each day was significantly associated with EWL (adjusted OR, 95% CI: 1.6,
54
55
56
57
58
59
60

1
2
3 1.1–2.3; 0.8, 0.7–0.9; and 0.7, 0.6–0.8 at 24, 48 and 72 hours, respectively). We obtained
4
5 similar estimates for Models 2 and 3.
6
7

8 9 10 **Differences in EWL by Dose**

11
12 At 24 hours postpartum, the number of cases of EWL was too small to examine specific
13
14 crystalloids doses. However, neither colloids doses nor total IV fluids doses were
15
16 associated significantly with EWL (Table IV). At 48 and 72 hours postpartum, we
17
18 observed no significant association between colloids, crystalloids or total IV fluids and
19
20 EWL, with the exception of a marginal protective effect from EWL at 72 hours
21
22 postpartum for crystalloids at doses >1000-2000 (adjusted OR: 0.2; 95% CI: <0.1–0.9).
23
24
25 No trend or dose-response relationship was observed with the increase in doses of
26
27 intrapartum IV fluids (Table IV). Results from the 3 sensitivity analyses supported the
28
29 primary analyses estimates (available in supplementary data Tables E1 to E5)).
30
31
32
33
34
35

36 **DISCUSSION**

37
38 This comparative safety study revealed two main findings. First, the newborn weight loss
39
40 and the risk of EWL did not differ when colloids plus crystalloids or crystalloids only IV
41
42 fluids were administered intrapartum for caesarean delivery. Second, there was no dose-
43
44 response relationship between colloids, crystalloids or total IV fluids and an increased
45
46 risk of EWL. The results were consistent in different models and sensitivity analyses on
47
48 exclusively breastfed newborns and EWL of >5% and >10% showed similar results.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 To the best of our knowledge, this study is the first to compare the risk of EWL for
5
6 different types of intrapartum IV fluids for caesarean delivery. Previous studies have
7
8 demonstrated comparable neonatal safety profiles of colloids versus crystalloids,
9
10 specifically for neonatal acidosis (risk ratio [RR] 0.2; 95% CI 0.01-4.1) and Apgar score
11
12 (meta-analysis of 3 studies with 209 women: RR: 0.2; 95% CI 0.03-2.1).[1] Similarly, no
13
14 significant difference in Apgar score was found among neonates exposed to colloids plus
15
16 crystalloids versus crystalloids only (meta-analysis of 2 studies with 107 women: RR:
17
18 0.1; 95% CI 0.01-1.2).[1] Still, it is noteworthy that the number of events in those studies
19
20 was low and medications used in these older trials (e.g dextrans and gelatins) no longer
21
22 reflect the current practice of using HES as the preferred choice.[2,4,5] Recently, the
23
24 CAESAR trial compared two treatment regimens similar to the current study and reported
25
26 no difference in Apgar score or umbilical pH.[2]
27
28
29
30
31
32
33

34
35 Of nine published studies, five reported significant positive associations between doses of
36
37 intrapartum fluids and weight loss[11–14,19] whereas the other four reported no
38
39 significant relationships.[20–23] However, studies with significant findings are different
40
41 from the current study since they were based on vaginal births and breastfed
42
43 newborns[11,12,19] or very small sample sizes.[13,14] Our results corroborate the results
44
45 of one case-control[23], two prospective cohort studies[20,22], as well as the only RCT
46
47 on intrapartum IV fluids and EWL to date.[21]
48
49
50
51
52

53
54 Previous studies hypothesized that since fluids move freely from the mother to her fetus,
55
56 newborns may become overhydrated and a consequent correction for the newborns' fluid
57
58
59
60

1
2
3 balance is an increase in diuresis and weight loss.[20,24] This hypothesis was partially
4 supported by recent reports[11,12], but caution must be exercised as the observed weight
5 loss could be attributed to insufficient feeding, especially among exclusively breastfed
6 infants. Previous studies had suggested that the intrapartum administration of crystalloids
7 could significantly affect the onset of lactogenesis[12,15,25] through the development of
8 breast engorgement, which in turn could negatively affect milk production[25] and
9 increase breast edema.[26] However, our results suggest that if this is the case, it will not
10 lead to an increased risk of EWL. Future studies are warranted to fully examine the effect
11 of IV fluids – and their specific types – on lactogenesis and EWL. In the current study,
12 the rates of discharges (urine and stool) were comparable to similar studies published in
13 the literature.[20,23,27] A noteworthy finding is the significant association between
14 elective caesarean delivery and EWL. It is possible that pregnant women opting for an
15 elective caesarean delivery could have suffered from other obstetric conditions that leave
16 their newborns more prone to EWL.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 The present study has some important strengths. Our objective was to compare newborn
40 weight loss and EWL after two widely used prevention and treatment options for
41 hypotension during caesarean delivery. Through comparing similar IV fluid regimens,
42 and accounting for numerous potentially confounding variables, we minimized the
43 potential bias of confounding by indication, in this case hypotension itself. Indeed,
44 maternal hypotension itself – and the associated reduction in utero-placental blood supply
45 – can lead to fetal acidosis, which cause weak rooting and sucking reflexes. The later
46 factors can severely compromise lactogenesis, leading to significant newborn weight loss
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 that can be erroneously attributed to IV fluids exposure.[1,28–30] In addition, we used a
4
5 large set of statistical models and sensitivity analyses to confirm the validity of our
6
7
8 observed estimates. However, the results should be interpreted with consideration of the
9
10 following limitations. The retrospective design has its limitations compared to a
11
12 prospective study with efficient follow-up. We were unable to distinguish between pre-
13
14 and co-loading of IV fluids administered. We did not have data on intrapartum oral fluids
15
16 nor the exact onset of successful exclusive breastfeeding (day 1, 2, or 3) and other related
17
18 factors (e.g. latching, dysfunctional sucking, etc.). We did not have data on the degree of
19
20 hypertension, the fluid regimens before the caesarean delivery decision, nor the specific
21
22 indications for caesarean delivery. The study was underpowered for some of the
23
24 secondary analyses and future larger studies are warranted. Moreover, different tests were
25
26 performed and no correction was applied for multiple testing. The study was conducted in
27
28 one hospital center in Canada, and results may not be directly generalizable to other
29
30 hospital settings. Given that this is a comparative safety study with an active treatment
31
32 regimen as a reference group, we cannot exclude the possibility that both IV fluid
33
34 regimens have a deleterious effect on newborn weight loss. We used penalized
35
36 maximum likelihood estimation, which produces the best estimates given the available
37
38 information.[31] However, given the very limited number of cases in some of the full
39
40 models, effect estimates differed from crude models among some variables, with
41
42 exceedingly inflated variance. The effect estimates of the primary and secondary
43
44 exposures on the dependent variable (i.e. EWL) are nonetheless valid since the full
45
46 models were bias adjusted using penalization.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In summary, in the current comparative safety study, the difference in weight loss and the risk of EWL were similar with colloids plus crystalloids and crystalloids intrapartum IV fluids among women undergoing caesarean delivery. The absence of dose-response relationships between both IV fluids types and EWL adds confirmatory evidence to their safety profiles. Future prospective studies are warranted to confirm the current study results. Combined with previous studies, these results suggest that both therapeutic options can be considered as safe during caesarean sections.

Acknowledgements We thank Mr. Hamza Abdelalim for assistance with the data collection process.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are available after discussion with the Oracle Study Investigators in accordance with our data-sharing policy.

Contribution to Authorship SE, ABa, BS, SD, AM, WH, ABl and MB have contributed to the concept and design of the study. SE and MB performed the analysis and drafted the first draft. SE, ABa, BS, SD, AM, WH, ABl and MB participated in the interpretation of the data. SE, ABa, BS, SD, AM, WH, ABl and MB contributed in drafting and revising of the full manuscript, and have approved the manuscript as submitted. SE, ABa, BS, SD, AM, WH, ABl and MB have met the criteria of authorship, and take public responsibility for the study contents.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ethics Approval This research project was approved by the Research Ethics Committee of the Vitalité Health Network (first approval 23-12-2009, amendment approved on 26-5-2016).

Funding S.E. is the recipient of the New Brunswick Health Research Foundation and Canadian Institutes for Health Research-Strategy for Patient Oriented Research-Maritime SPOR SUPPORT Unit Post-Doctoral Fellowship award.

What is already known on this topic?

- Use of intravenous fluids (i.e. crystalloids and colloids) prior to and/or during anesthesia is a common strategy to prevent maternal hypotension during caesarean sections.
- Published literature provides conflicting evidence of association between intravenous fluids – specifically crystalloids – and excess weight loss.

What this study adds?

- Weight loss difference and the risk of excess weight loss were similar with colloids plus crystalloids and crystalloids among women undergoing caesarean delivery.
- No dose-response relationship observed between colloids, crystalloids or total intravenous fluids and an increased risk of excess weight loss.
- Primary and sensitivity analyses suggest that both therapeutic options can be considered as safe during caesarean sections.

References

- 1 Cyna AM, Andrew M, Emmett RS, *et al.* Techniques for preventing hypotension during spinal anaesthesia for caesarean section. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd 2006.
doi:10.1002/14651858.CD002251.pub2
- 2 Mercier FJ, Diemunsch P, Ducloy-Bouthors AS, *et al.* 6% Hydroxyethyl starch (130/0.4) vs Ringer's lactate preloading before spinal anaesthesia for Caesarean delivery: The randomized, double-blind, multicentre CAESAR trial. *Br J Anaesth* 2014;**113**:459–67. doi:10.1093/bja/aeu103
- 3 Teoh WHL, Westphal M, Kampmeier TG. Update on volume therapy in obstetrics. *Best Pract Res Clin Anaesthesiol* 2014;**28**:297–303. doi:10.1016/j.bpa.2014.07.004
- 4 Mercier FJ. Cesarean delivery fluid management. *Curr Opin Anaesthesiol* 2012;**25**:286–91. doi:10.1097/ACO.0b013e3283530dab
- 5 Ripolles Melchor J, Espinosa, Martinez Hurtado E, *et al.* Colloids versus crystalloids in the prevention of hypotension induced by spinal anesthesia in elective cesarean section. A systematic review and meta-analysis. *Minerva Anesthesiol.* 2015;**81**:1019–30.
- 6 Flaherman VJ, Schaefer EW, Kuzniewicz MW, *et al.* Early weight loss nomograms for exclusively breastfed newborns. *Pediatrics* 2015;**135**:16–23.
doi:10.1542/peds.2014-1532
- 7 Miller JR, Flaherman VJ, Schaefer EW, *et al.* Early weight loss nomograms for formula fed newborns. *Hosp Pediatr* 2015;**5**:263–8. doi:10.1542/hpeds.2014-0143

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 8 Moritz ML, Manole MD, Bogen DL, *et al.* Breastfeeding-associated hypernatremia: are we missing the diagnosis? *Pediatrics* 2005;**116**:e343–7. doi:10.1542/peds.2004-2647
- 9 Escobar GJ, V.M G, Armstrong MA, *et al.* Rehospitalization for neonatal dehydration: A nested case-control study. *Arch Pediatr Adolesc Med* 2002;**156**:155–61. doi:poa10396 [pii]
- 10 Van Amerongen RH, Moretta AC, Gaeta TJ. Severe hypernatremic dehydration and death in a breast-fed infant. *Pediatr Emerg Care* 2001;**17**:175–80. doi:10.1097/00006565-200106000-00006
- 11 Chantry CJ, Nommsen-Rivers LA, Peerson JM, *et al.* Excess Weight Loss in First-Born Breastfed Newborns Relates to Maternal Intrapartum Fluid Balance. *Pediatrics* 2011;**127**:e171–9. doi:10.1542/peds.2009-2663
- 12 Noel-Weiss J, Woodend a K, Peterson WE, *et al.* An observational study of associations among maternal fluids during parturition, neonatal output, and breastfed newborn weight loss. *Int Breastfeed J* 2011;**6**:9. doi:10.1186/1746-4358-6-9
- 13 Hirth R, Weitkamp T, Dwivedi A. Maternal Intravenous Fluids and infant weight. *Clin Lact* 2012;:59–63.
- 14 Sheehan K FB. The Role of Intrapartum Intravenous Therapy and Newborn Weight Loss: Challenging the 7% Rule. *Clin Mother Child Heal* 2015;**12**:8–12. doi:10.4172/2090-7214.1000181
- 15 Dewey KG, Nommsen-rivers LA, Heinig MJ, *et al.* Risk Factors for Suboptimal Infant Breastfeeding Behavior, Delayed Onset of Lactation, and Excess Neonatal

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Weight Loss. *Pediatrics* 2003;**112**.
- 16 Firth D. Bias Reduction of Maximum-Likelihood-Estimates. *Biometrika* 1993;**80**:27–38. doi:10.1093/biomet/80.1.27
- 17 Tawia S, Mcguire L. Early weight loss and weight gain in healthy , full-term , exclusively-breastfed infants. *Breastfeed Rev* 2014;**22**:31–42.
- 18 Mezzacappa MA, Ferreira BG. Excessive weight loss in exclusively breastfed full-term newborns in a Baby-Friendly Hospital. *Rev Paul Pediatr (English Ed)* 2016;**34**:281–6. doi:10.1016/j.rppede.2016.03.003
- 19 Moen V, Brudin L, Rundgren M, *et al*. Hyponatremia complicating labour--rare or unrecognised? A prospective observational study. *BJOG* 2009;**116**:552–61. doi:10.1111/j.1471-0528.2008.02063.x
- 20 Lamp JM, Macke JK. Relationships among intrapartum maternal fluid intake, birth type, neonatal output, and neonatal weight loss during the first 48 hours after birth. *J Obstet Gynecol Neonatal Nurs* 2010;**39**:169–77. doi:10.1111/j.1552-6909.2010.01106.x
- 21 Watson J, Hodnett E, Armson BA, *et al*. A randomized controlled trial of the effect of intrapartum intravenous fluid management on breastfed newborn weight loss. *J Obstet Gynecol Neonatal Nurs* 2012;**41**:24–32. doi:10.1111/j.1552-6909.2011.01321.x
- 22 Grossman X, Chaudhuri JH, Feldman-Winter L, *et al*. Neonatal Weight Loss at a US Baby-Friendly Hospital. *J Acad Nutr Diet* 2012;**112**:410–3. doi:10.1016/j.jada.2011.10.024
- 23 Thulier DJ. Maternal hydration and infant weight: A case-control study in

- breastfeeding infants delivered by cesarean section. *ProQuest Diss Theses* 2013;:126.http://digitalcommons.uri.edu/oa_diss
- 24 Zetterström R. Excessive fluid intake before and during delivery causing water intoxication in the mother and her offspring. *Acta Paediatr* 2007;**91**:867–8. doi:10.1111/j.1651-2227.2002.tb02846.x
- 25 Cotterman KJ. Reverse Pressure Softening: A Simple Tool to Prepare Areola for Easier Latching During Engorgement. *J Hum Lact* 2004;**20**:227–37. doi:10.1177/0890334404264224
- 26 Kujawa-Myles S, Noel-Weiss J, Dunn S, *et al.* Maternal intravenous fluids and postpartum breast changes: a pilot observational study. *Int Breastfeed J* 2015;**10**:18. doi:10.1186/s13006-015-0043-8
- 27 Mulder PJ, Johnson TS, Baker LC. Excessive weight loss in breastfed infants during the postpartum hospitalization. *JOGNN - J Obstet Gynecol Neonatal Nurs* 2010;**39**:15–26. doi:10.1111/j.1552-6909.2009.01085.x
- 28 Lyons G. Epidural is an outmoded form of regional anaesthesia for elective caesarean section. *Proposer. Int J Obstet Anesth* 1995;**4**:34–6.
- 29 Robson SC, Boys RJ, Rodeck C, *et al.* Maternal and fetal haemodynamic effects of spinal and extradural anaesthesia for elective caesarean section. *Br J Anaesth* 1992;**68**:54–9.
- 30 Roberts SW, Leveno KJ, Sidawi JE, *et al.* Fetal acidemia associated with regional anesthesia for elective cesarean delivery. *Obstet Gynecol* 1995;**85**:79–83.
- 31 Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. *BMJ* 2016;:i1981. doi:10.1136/bmj.i1981

Table I. Characteristics of Mothers-Infants Pairs According to Intrapartum Colloids and Crystalloids Exposure for Caesarean Section

	Missing data	Colloids plus Crystalloids	Crystalloids only
	No. (%)	No. of deliveries (%)	
		176 (22.0)	625 (78.0)
Gestational and maternal variables			
Maternal age in years (Mean ± SD)	0 (0)	29.7 (±4.9)	29.2 (±5.2)
≤35		155 (88.1)	547 (87.5)
>35		21 (11.9)	78 (12.5)
Gravida	2 (0.2)		
1		89 (50.9)	285 (45.7)
2-4		79 (45.1)	311 (49.8)
≥5		7 (4.0)	28 (4.5)
Para	2 (0.2)		
0		104 (59.4)	363 (58.2)
1		55 (31.4)	200 (32.0)
≥2		16 (9.2)	61 (9.8)
Abortus	2 (0.2)		
0		135 (77.1)	439 (70.4)
1		33 (18.9)	128 (20.5)
≥2		7 (4.0)	57 (9.1)
Cigarette smoking	2 (0.2)	21 (11.9)	105 (16.9)
Alcohol drinking	4 (0.5)	14 (8.0)	85 (13.7)
Drug use	4 (0.5)	6 (3.4)	24 (3.9)
Gestational diabetes	0 (0)	5 (2.8)	38 (6.1)
Hypertension during pregnancy	0 (0)	9 (5.1)	41 (6.6)
Pre-eclampsia	0 (0)	11 (6.3)	29 (4.6)
Epidural before caesarean section	0 (0)	53 (30.1)	272 (43.5)
Elective caesarean section	4 (0.5)	73 (41.7)	233 (37.5)
Infant related variables			
Birth weight in grams (Mean ± SD)	12 (1.5)	3383 (±572)	3449 (±544)
Gestational age in weeks (Mean ± SD)	12 (1.5)	38.6 (±1.4)	39.0 (±1.6)
Preterm delivery	12 (1.5)	19 (11.1)	43 (7.0)
Low Apgar score (< 7) at 1 min	14 (1.7)	8 (4.7)	34 (5.5)
Fever during hospitalization	14 (1.7)	4 (2.3)	11 (1.8)
Phototherapy on day 1	13 (1.6)	5 (2.9)	9 (1.5)
Phototherapy on day 2	13 (1.6)	9 (5.2)	21 (3.4)
Phototherapy on day 3	14 (1.7)	18 (10.5)	36 (5.9)
Exclusive breastfeeding during hospitalization	15 (1.9)	46 (26.9)	290 (47.2)
Urine during day 1 (Mean ± SD)	15 (1.9)	2.5 (±1.9)	2.8 (±1.8)
Urine during day 2 (Mean ± SD)	17 (2.1)	4.0 (±1.7)	3.8 (±1.7)
Urine during day 3 (Mean ± SD)	73 (9.1)	4.1 (±1.7)	4.0 (±1.8)

Stools during day 1 (Mean ± SD)	15 (1.9)	2.5 (±1.6)	2.6 (±1.6)
Stools during day 2 (Mean ± SD)	17 (2.1)	3.4 (±1.7)	3.0 (±1.5)
Stools during day 3 (Mean ± SD)	73 (9.1)	3.0 (±1.6)	3.0 (±1.6)
Colloids doses in ml*	1 (0.1)		
0		0 (0)	625 (78.1)
>0-500		47 (5.9)	-
>500		128 (16.0)	-
Crystalloids doses in ml	26 (3.2)		
0		16 (2.1)*	0 (0)
>0-1000		54 (7.0)	168 (21.7)
>1000-2000		84 (10.8)	320 (41.3)
>2000		18 (2.3)	115 (14.8)
Total IV fluid doses in ml	26 (3.2)		
>0-1000		22 (2.8)	168 (21.7)
>1000-2000		102 (13.2)	320 (41.3)
>2000-3000		42 (5.4)	108 (13.9)
>3000		6 (0.8)	7 (0.9)

*Deliveries with missing data on crystalloids doses but available data on colloids doses (16 patients' records) were included in the Colloids plus Crystalloids group in the statistical analysis.

Table II. Beta Coefficients and 95% Confidence Intervals of the Linear Regression Models for Difference in Weight at 24, 48, and 72 Hours Postpartum According to Maternal Intrapartum Colloids and Crystalloids Exposure

	Difference in weight in grams (β and 95% CI)					
	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	<i>Model 1 (crude)</i>	<i>Model 3</i>	<i>Model 1 (crude)</i>	<i>Model 3</i>	<i>Model 1 (crude)</i>	<i>Model 3</i>
Colloids plus Crystalloids	-0.6 (-12.6, 11.4)	-5.2 (-17.5, 7.0)	-0.4 (-15.9, 15.0)	-10.8 (-26.1, 4.5)	-5.4 (-28.2, 17.4)	-9.2 (-32.0, 13.7)
Crystalloids only	Reference	Reference	Reference	Reference	Reference	Reference
Colloids doses in ml (vs 0)						
>0-500	-5.8 (-27.9, 16.4)	-9.3 (-31.3, 12.7)	-3.1 (-31.9, 25.7)	-9.5 (-37.3, 18.3)	-11.0 (-55.5, 33.4)	-13.1 (-56.8, 30.6)
>500	-0.4 (-14.6, 13.8)	-5.8 (-20.1, 8.5)	1.6 (-16.8, 20.1)	-9.8 (-27.8, 8.1)	-8.2 (-35.2, 18.8)	-7.9 (-34.5, 18.7)
Crystalloids doses in ml (vs 0)						
>0-1000	4.2 (-33.0, 41.4)	-2.6 (-40.9, 35.7)	5.0 (-43.3, 53.3)	13.9 (-34.3, 62.1)	-0.03 (-73.6, 73.5)	39.8 (-35.6, 115.1)
>1000-2000	2.9 (-33.9, 39.6)	-1.5 (-39.4, 36.4)	9.5 (-38.2, 57.2)	21.9 (-25.8, 69.6)	-7.6 (-80.1, 64.9)	39.5 (-35.1, 114.1)
>2000	-0.5 (-38.8, 37.8)	-6.8 (-46.0, 32.4)	2.8 (-46.9, 52.6)	9.8 (-39.4, 59.1)	-21.6 (-97.2, 53.9)	15.2 (-61.5, 91.9)
Total IV fluid doses in ml: (vs >0-1000)						
>1000-2000	-4.5 (-16.6, 7.6)	-2.9 (-15.0, 9.2)	4.3 (-11.5, 20.1)	8.1 (-7.1, 23.3)	-7.4 (-31.7, 17.0)	3.5 (-20.2, 27.3)
>2000-3000	-1.6 (-16.9, 13.7)	-2.7 (-17.8, 12.3)	0.8 (-19.1, 20.7)	-0.3 (-19.2, 18.6)	-24.8 (-54.6, 4.9)	-22.1 (-50.9, 6.6)
>3000	-26.7 (-67.7, 14.3)	-27.3 (-66.9, 12.2)	-14.4 (-38.9, 67.7)	-6.4 (-43.4, 56.2)	-3.9 (-81.1, 73.3)	-0.6 (-73.0, 71.8)

The regression coefficient represents the estimated difference in weight since birth

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

Model 3 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, election to have a caesarean section, Apgar score, exclusive breastfeeding, number of stools, number of urine, presence of fever and phototherapy.

Table III. Adjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) for Excess Weight Loss (>7%) According to Type of Intrapartum IV Fluid Received by Mothers for Caesarean Section

	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)</i>	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>
Colloids plus Crystalloids	0.9 (0.2–3.2)	1.0 (0.3–3.3)	0.9 (0.6–1.3)	1.0 (0.7–1.5)	1.3 (0.9–2.0)	1.4 (0.9–2.2)
Crystalloids only	Reference	Reference	Reference	Reference	Reference	Reference
Maternal age in years	0.9 (0.8–1.0)	1.0 (0.9–1.1)	1.0 (>0.9–1.1<)	1.0 (>0.9–1.0)	1.0 (>0.9–1.1)	1.0 (>0.9–1.1)
Gravida	0.9 (0.6–1.4)	0.3 (0.1–>99)	0.9 (0.8–1.0)	0.7 (0.2–2.5)	0.8 (0.7–0.9)	8.8 (0.7–>99)
Para	0.9 (0.4–1.8)	3.8 (<0.1–24.6)	0.8 (0.7–1.0)	1.2 (0.3–4.7)	0.7 (0.5–0.8)	0.1 (<0.1–0.8)
Abortus	0.9 (0.4–1.8)	3.3 (<0.1–19.7)	0.9 (0.7–1.1)	1.3 (0.4–5.0)	0.8 (0.6–1.0)	0.1 (<0.1–1.2)
Gestational age	1.1 (0.8–1.6)	0.9 (0.6–1.4)	1.1 (1.0–1.3)	1.0 (0.9–1.2)	1.1 (1.0–1.2)	0.9 (0.8–1.1)
Cigarette smoking	2.8 (0.9–8.3)	1.9 (0.5–5.9)	0.7 (0.5–1.1)	0.8 (0.5–1.3)	0.5 (0.3–0.7)	0.7 (0.4–1.2)
Drug use	4.2 (0.9–19.7)	2.8 (0.4–13.6)	0.7 (0.3–1.5)	0.6 (0.3–1.6)	1.1 (0.5–2.6)	1.3 (0.5–3.4)
Alcohol drinking	1.1 (0.2–4.8)	1.0 (0.2–3.7)	1.1 (0.7–1.8)	1.1 (0.7–1.7)	1.2 (0.7–1.9)	1.1 (0.7–2.0)
Hypertension during pregnancy	0.5 (<0.1–3.7)	0.2 (<0.1–2.6)	0.5 (0.3–1.0)	0.6 (0.3–1.3)	0.7 (0.4–1.3)	0.5 (0.2–1.1)
Gestational diabetes	1.3 (0.2–10.1)	1.6 (0.2–7.3)	1.2 (0.6–2.2)	1.4 (0.7–2.8)	0.7 (0.4–1.5)	1.2 (0.5–3.0)
Pre-eclampsia	1.4 (0.2–10.7)	3.8 (0.3–22.8)	0.4 (0.2–0.8)	0.6 (0.2–1.4)	1.1 (0.5–2.0)	1.5 (0.7–3.5)
Epidural before caesarean section	1.3 (0.5–3.6)	0.9 (0.2–3.6)	1.3 (0.9–1.6)	1.5 (1.0–2.4)	0.9 (0.6–1.2)	0.9 (0.5–1.4)
Elective caesarean section	0.6 (0.2–1.8)	0.6 (0.2–2.6)	1.2 (0.9–1.6)	1.7 (1.1–2.6)	1.3 (1.0–1.9)	1.8 (1.1–2.9)
Apgar score	1.4 (0.6–3.2)	1.2 (0.8–3.4)	1.2 (1.0–1.3)	1.2 (1.0–1.4)	1.1 (1.0–1.2)	1.1 (0.9–1.2)
Fever during hospitalization	1.6 (<0.1–13.2)	1.5 (<0.1–13.6)	2.6 (0.9–7.8)	3.3 (1.1–10.4)	0.8 (0.3–2.3)	1.0 (0.3–3.1)
Exclusive breastfeeding during hospitalization	0.7 (0.2–2.0)	0.9 (0.3–2.7)	1.3 (1.0–1.8)	1.1 (0.8–1.5)	1.6 (1.1–2.1)	1.5 (1.0–2.2)

Phototherapy on day 1	4.0 (0.5–32.9)	7.7 (0.7–46.1)	1.1 (0.4–3.1)	1.4 (0.4–4.8)	0.3 (0.1–1.1)	0.3 (0.1–1.2)
Phototherapy on day 2	N/A	N/A	1.1 (0.5–2.3)	1.6 (0.7–3.9)	0.9 (0.4–2.0)	1.7 (0.7–4.4)
Phototherapy on day 3	N/A	N/A	N/A	N/A	0.7 (0.4–1.3)	0.8 (0.4–1.6)
Urine during day 1	1.0 (0.8–1.4)	0.8 (0.6–1.2)	1.0 (0.9–1.1)	1.0 (0.9–1.2)	1.0 (0.9–1.1)	1.1 (1.0–1.2)
Urine during day 2	N/A	N/A	0.8 (0.8–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.0)
Urine during day 3	N/A	N/A	N/A	N/A	0.8 (0.7–0.9)	0.9 (0.8–1.0)
Stools during day 1	1.5 (1.1–2.1)	1.6 (1.1–2.3)	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.0 (0.9–1.1)	1.0 (0.8–1.1)
Stools during day 2	N/A	N/A	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.9 (0.8–1.0)
Stools during day 3	N/A	N/A	N/A	N/A	0.7 (0.6–0.8)	0.7 (0.6–0.8)

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

N/A: not applicable

*Firth penalized maximum likelihood estimation method was used for quasi-complete separation

Table IV. Crude and Adjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) for Excess Weight Loss (>7%) According to Doses of Intrapartum IV Fluid Received by Mothers for Caesarean Section

24 hours postpartum				48 hours postpartum			72 hours postpartum		
No. cases (%)	Model 1 (crude)OR (95% CI)*	Model 3 Adjusted OR (95% CI)*	No. cases (%)	Model 1 (crude)OR (95% CI)	Model 3 Adjusted OR (95% CI)	No. cases (%)	Model 1 (crude)OR (95% CI)	Model 3 Adjusted OR (95% CI)*	

Regression models for type-specific doses of IV fluid

Colloids doses (in ml)									
0	12 (2.0)	Reference	Reference	252 (41.9)	Reference	Reference	260 (53.8)	Reference	Reference
>0-500	2 (4.4)	3.3 (0.6–11.8)	2.7 (0.4–11.5)	17 (37.0)	0.9 (0.5–1.7)	1.0 (0.5–2.1)	20 (55.6)	1.1 (0.6–2.3)	1.3 (0.6–2.9)
>500	1 (0.8)	0.7 (0.1–2.8)	0.7 (0.1–3.1)	48 (39.7)	0.9 (0.6–1.4)	1.0 (0.6–1.5)	70 (62.5)	1.4 (0.9–2.1)	1.3 (0.8–2.1)
Crystalloids doses (in ml)									
0	0 (0.0)	Reference	Reference	6 (37.5)	Reference	Reference	9 (75.0)	Reference	Reference
>0-1000	3 (1.4)	N/A	N/A	92 (43.0)	1.1 (0.4–3.4)	0.8 (0.2–2.6)	93 (54.1)	0.5 (0.1–1.9)	0.2 (<0.1–1.1)
>1000-2000	10 (2.6)	N/A	N/A	156 (40.1)	1.0 (0.3–3.0)	0.6 (0.2–2.0)	179 (56.7)	0.5 (0.1–2.1)	0.2 (<0.1–0.9)
>2000	1 (0.8)	N/A	N/A	56 (44.8)	1.2 (0.4–3.8)	0.9 (0.2–3.0)	61 (55.0)	0.5 (0.1–2.1)	0.3 (<0.1–1.2)

Regression models for total doses of IV fluid

Total IV fluid doses (in ml)									
>0-1000	3 (1.7)	Reference	Reference	82 (44.8)	Reference	Reference	81 (55.5)	Reference	Reference
>1000-2000	8 (2.0)	1.1 (0.3–4.4)	1.1 (0.3–4.5)	161 (39.3)	0.8 (0.6–1.1)	0.7 (0.5–1.0)	183 (56.0)	1.0 (0.7–1.5)	0.8 (0.5–1.2)
>2000-3000	3 (2.2)	1.3 (0.3–6.3)	1.2 (0.2–6.1)	64 (45.7)	1.0 (0.7–1.6)	1.0 (0.6–1.6)	71 (55.9)	1.0 (0.6–1.6)	0.9 (0.5–1.6)
>3000	0 (0.0)	N/A	N/A	3 (27.3)	0.5 (0.1–1.8)	0.5 (0.1–2.0)	7 (63.6)	1.4 (0.4–5.0)	1.1 (0.3–4.6)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

Model 3 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, election to have a caesarean section, Apgar score, exclusive breastfeeding, number of stools, number of urine, presence of fever and phototherapy.


N/A: not applicable

Firth penalized maximum likelihood estimation method was used for quasi-complete separation

Figures legend

Figure 1. Cohort selection flow diagram

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



168x153mm (300 x 300 DPI)

View Only

Supplementary Tables: Intrapartum intravenous fluids for caesarean delivery and newborn weight loss: a retrospective cohort study

Table E1. Adjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) for Excess Weight Loss According to Type of Intrapartum IV Fluid Received by Mothers for Caesarean Section in Different Sensitivity Analysis

	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)</i>	<i>Model 1 crude OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>
Excess Weight Loss (>5%)						
Colloids plus Crystalloids	0.9 (0.5–1.4)	0.9 (0.5–1.5)	1.2 (0.8–1.8)	1.4 (0.9–2.3)	1.4 (0.8–2.3)	1.5 (0.9–2.8)
Crystalloids only	Reference	Reference	Reference	Reference	Reference	Reference
Excess Weight Loss (>10%)						
Colloids plus Crystalloids	0.5 (<0.1–5.2)	0.4 (<0.1–4.7)	1.1 (0.4–3.4)	1.0 (0.3–3.0)	1.1 (0.7–1.8)	0.9 (0.5–1.5)
Crystalloids only	Reference	Reference	Reference	Reference	Reference	Reference
Among Exclusively Breastfed newborns						
Colloids plus Crystalloids	0.6 (<0.1–5.4)	0.5 (<0.1–3.9)	0.5 (0.3–1.0)	0.6 (0.3–1.2)	1.4 (0.7–3.1)	1.6 (0.7–3.9)
Crystalloids only	Reference	Reference	Reference	Reference	Reference	Reference

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, first pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

N/A: not applicable

*Firth penalized maximum likelihood estimation method was used for quasi-complete separation

bmjpo-2017-000070 on 1 August 2018. Downloaded from <http://bmjpaediatrics.bmj.com/> on April 11, 2024 by guest. Protected by copyright.

Table E2. Crude and Adjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) for Excess Weight Loss (>5%) According to Doses of Intrapartum IV Fluid Received by Mothers for Caesarean Section

	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	<i>Model 1 (crude)OR (95% CI)*</i>	<i>Model 3 Adjusted OR (95% CI)*</i>	<i>Model 1 (crude)OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)</i>	<i>Model 1 (crude)OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>
Regression models for type-specific doses of IV fluid						
Colloids doses (in ml)						
0	Reference	Reference	Reference	Reference	Reference	Reference
>0-500	0.7 (0.3–1.7)	0.9 (0.3–2.1)	1.1 (0.5–2.4)	1.3 (0.5–2.9)	1.5 (0.6–4.1)	1.4 (0.5–2.9)
>500	0.9 (0.5–1.6)	1.0 (0.5–1.7)	1.1 (0.7–1.9)	1.4 (0.8–2.6)	1.6 (0.9–2.8)	1.6 (0.8–2.1)
Crystalloids doses (in ml)						
0	Reference	Reference	Reference	Reference	Reference	Reference
>0-1000	0.6 (0.2–2.1)	0.7 (0.2–3.2)	1.1 (0.3–4.3)	0.9 (0.2–4.5)	1.1 (0.2–5.5)	0.6 (0.1–3.5)
>1000-2000	0.4 (0.1–1.5)	0.5 (0.1–2.4)	0.9 (0.2–3.2)	0.6 (0.1–3.1)	1.3 (0.3–6.3)	0.6 (0.1–3.2)
>2000	0.6 (0.2–2.2)	0.8 (0.2–3.8)	0.9 (0.2–3.5)	0.8 (0.2–4.3)	1.2 (0.2–6.2)	0.7 (0.1–4.1)
Regression models for total doses of IV fluid						
Total IV fluid doses (in ml)						
>0-1000	Reference	Reference	Reference	Reference	Reference	Reference
>1000-2000	0.7 (0.5–1.2)	0.8 (0.5–1.3)	0.8 (0.5–1.3)	0.7 (0.4–1.2)	1.2 (0.7–1.9)	0.9 (0.5–1.6)
>2000-3000	0.9 (0.5–1.6)	1.1 (0.6–1.9)	0.8 (0.5–1.4)	0.9 (0.5–1.6)	1.2 (0.6–2.1)	1.1 (0.5–2.1)
>3000	2.5 (0.7–8.2)	2.8 (0.7–9.8)	1.1 (0.2–5.1)	1.7 (0.3–10.0)	1.2 (0.2–5.9)	0.9 (0.2–5.6)

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Downloaded from <http://bmjpaedsopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, post pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

Model 3 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, post pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, election to have a caesarean section, Apgar score, breastfeeding, number of stools, number of urine, presence of fever and phototherapy.

N/A: not applicable

*Firth penalized maximum likelihood estimation method was used for quasi-complete separation

Confidential: For Review Only

Table E3. Crude and Adjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) for Excess Weight Loss (>10%) According to Doses of Intrapartum IV Fluid Received by Mothers for Caesarean Section

	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	<i>Model 1 (crude)OR (95% CI)*</i>	<i>Model 3 Adjusted OR (95% CI)*</i>	<i>Model 1 (crude)OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)</i>	<i>Model 2 (crude)OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>
Regression models for type-specific doses of IV fluid						
Colloids doses (in ml)						
0	Reference	Reference	Reference	Reference	Reference	Reference
>0-500	1.5 (<0.1–20.6)	0.5 (<0.1–12.4)	0.5 (<0.1–1.7)	0.4 (<0.1–3.3)	0.8 (0.3–2.3)	0.7 (0.2–1.9)
>500	0.6 (<0.1–6.8)	0.7 (<0.1–7.9)	1.7 (0.5–1.4)	1.4 (0.4–4.5)	1.0 (0.6–1.8)	0.8 (0.4–1.5)
Crystalloids doses (in ml)						
0	Reference	Reference	Reference	Reference	Reference	Reference
>0-1000	0.2 (<0.1–44.8)	0.1 (<0.1–27.2)	0.7 (0.1–3.4)	0.7 (<0.1–96.5)	0.3 (0.1–1.3)	0.2 (<0.1–0.8)
>1000-2000	0.2 (<0.1–36.4)	0.1 (<0.1–32.1)	1.2 (0.1–3.0)	1.1 (0.1–159.4)	0.4 (0.1–1.4)	0.2 (<0.1–0.7)
>2000	0.1 (<0.1–28.5)	0.1 (<0.1–29.6)	0.5 (<0.1–3.8)	0.3 (<0.1–57.9)	0.3 (0.1–1.2)	0.2 (<0.1–0.8)
Regression models for total doses of IV fluid						
Total IV fluid doses (in ml)						
>0-1000	Reference	Reference	Reference	Reference	Reference	Reference
>1000-2000	0.7 (0.1–8.1)	0.9 (0.1–15.9)	2.7 (0.8–13.5)	2.6 (0.8–12.8)	0.9 (0.6–1.6)	0.7 (0.4–1.3)
>2000-3000	0.4 (<0.1–8.2)	0.7 (<0.1–22.5)	0.8 (0.1–5.9)	0.6 (0.1–4.9)	0.9 (0.4–1.7)	0.8 (0.4–1.6)
>3000	5.2 (<0.1–103.4)	3.2 (<0.1–151.2)	3.2 (<0.1–41.9)	4.3 (<0.1–60.6)	0.2 (<0.1–1.7)	0.2 (<0.1–1.6)

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

bmjpo-2017-000070 on 15 August 2017. Downloaded from <http://bmjpaedsopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4
5 Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational
6 age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

7 Model 3 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational
8 age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, election to have a caesarean section, Apgar score,
9 breastfeeding, number of stools, number of urine, presence of fever and phototherapy.

10 N/A: not applicable

11 *Firth penalized maximum likelihood estimation method was used for quasi-complete separation

Confidential: For Review Only

Table E4. Crude and Adjusted Odds Ratios (OR) and 95% Confidence Intervals (CI) for Excess Weight Loss (>7%) According to Doses of Intrapartum IV Fluid Received by Mothers for Caesarean Section among Exclusively Breastfed Newborns

	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	<i>Model 1 (crude)OR (95% CI)*</i>	<i>Model 3 Adjusted OR (95% CI)*</i>	<i>Model 1 (crude)OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)</i>	<i>Model 1 (crude)OR (95% CI)</i>	<i>Model 3 Adjusted OR (95% CI)*</i>
Regression models for type-specific doses of IV fluid						
Colloids doses (in ml)						
0	Reference	Reference	Reference	Reference	Reference	Reference
>0-500	2.3 (<0.1–35.3)	2.0 (<0.1–38.2)	0.8 (0.2–2.8)	1.2 (0.3–4.6)	1.1 (0.3–4.7)	NA [§]
>500	1.0 (<0.1–9.8)	0.6 (<0.1–5.9)	0.5 (0.2–1.1)	0.6 (0.3–1.3)	1.7 (0.8–4.3)	NA [§]
Crystalloids doses (in ml)						
0	Reference	Reference	Reference	Reference	Reference	Reference
>0-1000	0.3 (<0.1–89.5)	0.2 (<0.1–76.9)	1.8 (0.3–21.5)	1.9 (0.2–25.6)	1.8 (0.1–16.2)	NA [§]
>1000-2000	0.4 (<0.1–90.8)	0.3 (<0.1–89.4)	1.8 (0.3–20.4)	1.4 (0.2–18.5)	1.2 (0.1–10.3)	NA [§]
>2000	0.2 (<0.1–56.6)	0.1 (<0.1–48.8)	2.1 (0.3–24.7)	1.9 (0.2–25.7)	1.4 (0.1–12.9)	NA [§]
Regression models for total doses of IV fluid						
Total IV fluid doses (in ml)						
>0-1000	Reference	Reference	Reference	Reference	Reference	Reference
>1000-2000	1.1 (0.2–11.5)	1.2 (0.2–10.8)	0.9 (0.5–1.5)	0.7 (0.4–1.3)	0.7 (0.4–1.4)	0.7 (0.3–1.4)
>2000-3000	0.5 (<0.1–9.7)	0.5 (<0.1–6.4)	1.2 (0.6–2.4)	1.1 (0.5–2.3)	0.9 (0.4–2.1)	0.8 (0.3–1.9)
>3000	4.9 (<0.1–105.0)	1.8 (<0.1–70.0)	0.4 (<0.1–2.1)	0.3 (<0.1–1.8)	1.5 (0.3–5.9)	0.8 (0.1–9.2)

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

1
2
3
4
5 Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, post pregnancies, gestational
6 age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

7 Model 3 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, post pregnancies, gestational
8 age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, election to have a caesarean section, Apgar score, number
9 of stools, number of urine, presence of fever and phototherapy.

10 N/A: not applicable

11 *Firth penalized maximum likelihood estimation method was used for quasi-complete separation

12 § Models did not converge efficiently due to quasi-complete separation (i.e. impossible to estimate even with penalized maximum likelihood)

Table E5. Beta Coefficients and 95% Confidence Intervals of the Linear Regression Models for Difference in Weight at 24, 48, and 72 Hours Postpartum According to Maternal Intrapartum Colloids and Crystalloids Exposure among Exclusively Breastfed Newborns Only

	Difference in weight in grams (β and 95% CI)					
	24 hours postpartum		48 hours postpartum		72 hours postpartum	
	Model 1 (crude)	Model 3	Model 1 (crude)	Model 3	Model 1 (crude)	Model 3
Colloids plus Crystalloids	18.6 (-2.7, 39.8)	17.3 (-4.1, 38.7)	23.3 (-2.5, 49.0)	18.8 (-7.1, 44.7)	3.6 (-26.8, 34.0)	-2.5 (-33.9, 29.0)
Crystalloids only	Reference	Reference	Reference	Reference	Reference	Reference
Colloids doses in ml (vs 0)						
>0-500	29.4 (-15.1, 73.8)	23.3 (-21.3, 70.7)	18.3 (-35.9, 72.7)	20.8 (-33.3, 75.3)	-2.1 (-37.5, 32.4)	-17.1 (-87.8, 53.6)
>500	16.7 (-8.4, 41.7)	16.8 (-8.1, 41.5)	22.3 (-7.8, 52.1)	15.5 (-14.8, 45.1)	-4.1 (-60.2, 69.8)	-0.6 (-35.5, 36.7)
Crystalloids doses in ml (vs 0)						
>0-1000	34.3 (-52.3, 80.4)	20.6 (-52.9, 94.7)	-31.7 (-113.3, 53.3)	-18.9 (-107.3, 71.1)	-17.1 (-125.6, 90.5)	-3.8 (-131.6, 125.1)
>1000-2000	33.0 (-51.1, 81.6)	18.5 (-54.4, 91.4)	-20.5 (-101.2, 57.2)	-8.9 (-96.8, 79.6)	-4.6 (-101.1, 111.9)	20.5 (-105.1, 147.1)
>2000	-34.0 (-57.1, 78.8)	15.8 (-58.0, 89.4)	-27.8 (-110.9, 52.6)	-9.9 (-99.4, 80.0)	-13.1 (-122.2, 95.9)	13.2 (-115.5, 141.9)
Total IV fluid doses in ml: (vs >0-1000)						
>1000-2000	-1.5 (-18.6, 16.6)	-1.9 (-19.0, 15.2)	10.3 (-10.5, 31.1)	9.1 (-11.1, 30.3)	17.1 (-10.7, 44.0)	15.5 (-12.2, 42.3)
>2000-3000	-8.6 (-14.9, 31.7)	6.7 (-15.8, 29.3)	10.8 (-17.1, 38.7)	13.3 (-14.2, 40.6)	1.1 (-33.6, 36.9)	9.1 (-25.9, 45.6)
>3000	-64.9 (-125.6, -4.5)	-48.3 (-107.9, 11.2)	-15.4 (-89.9, 59.7)	-6.9 (-79.4, 65.2)	-22.1 (-104.1, 59.3)	13.6 (-67.0, 95.8)

The regression coefficient represents the estimated difference in weight since birth

Model 2 adjusted results were similar to the adjusted results of Model 3 (only results from Model 3 are presented in the table; results of Model 2 are available upon request)

Model 2 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, and election to have a caesarean section.

Model 3 adjusted for maternal age, gestational diabetes, hypertension during pregnancy, number of pregnancies, viable births, lost pregnancies, gestational age, pre-eclampsia, cigarette smoking, alcohol use, drug use, epidural before caesarean section, election to have a caesarean section, Apgar score, number of stools, number of urine, presence of fever and phototherapy.